f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche finance report finance report finance brief finance brief key results roche roche group reported good overall results sales grew constant exchange rates cer ifrs net income increased sales core operating profit margin cer growth sales core earnings per share pharmaceuticals sales diagnostics group sales increased cer chf billion growth chf terms pharmaceuticals sales growth cer due continued growth franchise mabtherarituxan oncology portfolio immunology sales actemraroactemra esbriet xolair increased avastin sales stable sales pegasys tarceva lucentis decreased due competitive pressure group diagnostics sales showed growth cer centralised point care solutions business major contributor operating results change sales chf chf chf cer core operating profit increased cer chf billion increase chf terms ifrs results research development expenditure grew cer chf billion core basis focus oncology immunology sales therapeutic areas research development costs represented group sales operating profit ifrs operating results include noncore expenses pretax chf billion major factors chf billion amortisation net income intangible assets chf billion impairment goodwill intangible assets chf billion global restructuring plans notably net income attributable roche shareholders pharmaceuticals divisions strategic realignment manufacturing network diluted eps chf dividend per share chf nonoperating results core results core net financial expenses decreased chf billion chf billion driven lower foreign exchange losses lower interest expenses research development partially offset higher losses bond redemptions core operating profit ifrs net financial expenses decreased chf billion chf billion result decrease core net financial expenses core eps chf ifrs net financial expenses included loss chf billion major debt restructuring free cash flow net income operating free cash flow free cash flow ifrs net income increased cer chf billion increase chf terms core earnings per share increased cer chf terms change chf chf chf cer net debt cash flows operating free cash flow remained strong chf billion underlying growth operating cash generation offset capitalisation higher capital expenditure increase net working capital higher investments intangible assets led decrease cer debt chf terms equity free cash flow decreased cer chf terms chf billion driven lower operating free cash flow higher pension contributions proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant exchange rates average rates year ended december definition cer see financial position core results core eps earnings per share exclude noncore items global restructuring plans amortisation impairment goodwill intangible assets net working capital increased cer due increase receivables driven increased sales due higher inventories allows assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given partly offset higher payables net debt decreased chf billion generated free cash flow offset dividends paid net debt percentage group refined calculation free cash flow exclude dividends line peer group free cash flow restated accordingly resulting total assets increase chf million free cash flow period impact operating free cash flow change definition free cash flow credit ratings strong moodys standard poors aa detailed breakdown see pages shareholder return dividends proposal made increase dividends chf per share represent th consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr minus representing combined performance share nonvoting equity securityfinancial review roche group roche group financial review roche group results finance brief inside cover finance brief sales billions chf core operating profit billions chf financial review cer growth sales roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles noncurrent liabilities operating segment information current liabilities net financial expense provisions contingent liabilities net income attributable roche shareholders billions chf core eps chf income taxes debt business combinations equity attributable roche shareholders global restructuring plans subsidiaries property plant equipment noncontrolling interests goodwill employee benefits intangible assets pensions postemployment benefits inventories equity compensation plans accounts receivable earnings per share nonvoting equity security marketable securities statement cash flows roche groups results showed sales growth constant exchange rates cer ifrs operating profit cash cash equivalents risk management core operating profit core eps sales increase driven pharmaceuticals divisions oncology portfolio noncurrent assets related parties especially franchise centralised point care solutions business diagnostics division current assets subsidiaries associates increased expenditure research development launch expenses new products offset income changes accounts payable significant accounting policies groups swiss pension plans additionally costs grew diagnostics division due expansion sequencing business operating free cash flow chf billion sales decrease due higher capital expenditure increase net working capital increased investments intangible assets report roche management internal control financial reporting sales pharmaceuticals division rose chf billion increase driven oncology portfolio especially statutory auditors report general meeting roche holding ltd basel franchise grew sales immunology grew actemraroactemra xolair increasing respectively sales pegasys tarceva lucentis declined competitive pressure regional growth significant report independent auditor internal control financial reporting us europe diagnostics sales grew consolidating divisions leading market position major growth area board directors roche holding ltd basel centralised point care solutions sales increasing molecular diagnostics tissue diagnostics sales increased respectively sales diabetes care decreased due continuing challenging market conditions us multiyear overview supplementary information ifrs operating profit increased pharmaceuticals division diagnostics division increases roche securities core operating profit respectively pharmaceuticals divisions cost sales increased manufacturing costs offset lower royalty expenses marketing distribution costs grew driven launch costs new products notably tecentriq ocrevus research development continued investments oncology especially cancer immunotherapy field immunology cost sales diagnostics division grew due unfavourable product mix higher costs external suppliers research development expenses increased sequencing molecular diagnostics businesses results divisions roche holding ltd basel positively impacted accounting effects changes groups swiss pension plans operating free cash flow chf billion remained strong growth cash generation businesses offset financial statements higher capital expenditure increase net working capital higher investments intangible assets capital expenditure included manufacturing investments us switzerland germany chugai also site development activities switzerland notes financial statements south san francisco campus increase net working capital came inventories increased spending launch preparations factors combined give decrease cer chf terms relative free appropriation available earnings cash flow chf billion decrease due lower operating free cash flow higher pension contributions statutory auditors report general meeting roche holding ltd basel core basis net financial expenses lower due reductions foreign exchange losses lower interest expenses ifrs basis additionally lower due comparative results including loss chf billion major debt restructuring groups effective tax rates higher due deferred tax impact arising tax rate changes roche finance report roche group financial review financial review roche group net income increased cer ifrs basis core basis addition items described core results sales ifrs results reflect impacts higher intangible asset impairment amortisation offset releases contingent consideration provisions sales increased cer chf usd chf billion sales pharmaceuticals division rose chf billion driven growth franchise well actemraroactemra mabtherarituxan esbriet xolair compared swiss franc weaker major currencies particular japanese yen us dollar sales grew regions particularly us europe franchise grew respectively overall avastin euro overall impact positive results expressed swiss francs compared constant exchange rates sales remained stable decrease us offset higher sales international region sales pegasys tarceva percentage point impact sales core operating profit percentage points core eps lucentis declined competitive pressure total chf billion recently launched products alecensa tecentriq cotellic added chf billion sales income statement sales diagnostics division chf billion increase cer consolidating leading market position major change change chf chf chf cer growth area centralised point care solutions formerly professional diagnostics represents half ifrs results divisions sales growth led immunodiagnostics business sales molecular diagnostics tissue diagnostics sales increased respectively diabetes care sales decreased impacted continuing challenging market conditions royalties operating income north america cost sales marketing distribution divisional operating results research development pharmaceuticals diagnostics corporate group general administration chf chf chf chf operating profit sales core operating profit financing costs margin sales financial income expense operating profit profit taxes margin sales operating free cash flow income taxes margin sales net income attributable divisional operating results development results compared roche shareholders noncontrolling interests pharmaceuticals diagnostics corporate group sales eps basic chf increase cer eps diluted chf core operating profit increase cer core results margin percentage point increase sales operating profit royalties operating income increase cer cost sales margin percentage point increase marketing distribution operating free cash flow research development increase cer general administration margin percentage point increase operating profit financing costs financial income expense core operating results profit taxes significant income item core results chf million changes groups pension plans income taxes switzerland chf million tax cer positive margin impact percentage points group percentage net income points pharmaceuticals division percentage points diagnostics division excluding item core operating profit grew group pharmaceuticals division declined diagnostics division attributable roche shareholders pharmaceuticals division divisions core operating profit increased cer ahead sales increase manufacturing noncontrolling interests costs sales grew result investments internal external biologics manufacturing network royalty expenses decreased due expiry patents increased expenditure research development especially oncology core eps basic chf immunology well launch expenses tecentriq ocrevus new products partly offset income core eps diluted chf swiss pension plan changes diagnostics division core operating profit increased cer increase sales cost sales higher unfavourable product mix due higher instrument placements higher costs external suppliers research development costs increased due sequencing business partly offset income swiss pension plan changes roche finance report roche finance report roche group financial review financial review roche group acquisitions impairment goodwill intangible assets roche group complete business combinations chf million noncore income impairment charges chf million pharmaceuticals division largest item chf million related release contingent consideration provisions mainly due partial reversal provisions related seragon trophos decision stop development one compound acquired part seragon acquisition following clinical data assessment acquisitions two intangible asset impairment charges chf million chf million related seragon trophos additionally first half chf million related delay development compound acquired part respectively offset provision reversal noted impairment goodwill intangible assets commentary trophos acquisition following regulatory feedback related releases contingent consideration provisions noncore costs also include expenses chf million chf million release esbriet inventory fair value two acquisitions increased income total chf million noted acquisitions commentary major adjustment fully unwound details given notes annual financial statements item impairment charge chf million one compound following portfolio reassessment diagnostics division recorded impairment charges chf million largest item impairment sequencing global restructuring plans product intangibles use chf million result decision stop product development commercialisation licence agreement alliance partner group continued implementation several major global restructuring plans initiated prior years notably strategic realignment pharmaceuticals divisions manufacturing network programmes address longterm strategy details given notes annual financial statements diagnostics division global restructuring plans costs incurred millions chf pensions postemployment benefits diagnostics site consolidation plans total operating income chf million recorded past service costs changes groups pension plans global restructuring costs switzerland announced june represents impact adjustment pension liability plan employeerelated costs changes amount chf million recorded pharmaceuticals division chf million diagnostics division site closure costs chf million corporate aftertax impact chf million pension contributions higher due reorganisation expenses additional contributions plans switzerland us ireland information groups pensions post total global restructuring costs employment benefits given note annual financial statements additional costs impairment goodwill legal environmental cases impairment intangible assets legal environmental cases legal environmental cases include increase provisions chf million environmental matters following divestment nutley site significant developments details given note annual financial total costs statements includes diabetes care autonomy speed restructuring plan includes pharmaceuticals division strategic realignment manufacturing network includes plans pharmaceuticals division research development strategic realignment outsourcing treasury taxation diagnostics division costs roche diabetes care autonomy speed initiative chf million mainly financing costs lower ifrs basis due loss comparative period chf million major debt consultancy itrelated matters well employeerelated costs new strategy plans diagnostics diabetes care incurred costs restructuring core basis financing costs chf billion driven lower interest expenses financial chf million related site closures employees spending smaller plans within division chf million income chf million including net income equity securities chf million mostly offset net foreign included costs related certain projects exchange losses chf million ifrs tax expenses chf billion increase core tax expenses increased chf billion groups effective core tax rate compared largely due deferred site consolidation pharmaceuticals division announced strategic realignment manufacturing network including tax impact arising tax rate changes exiting manufacturing sites clarecastle ireland legans spain segrate italy florence us costs plan chf million chf million noncash writedowns accelerated depreciation property plant equipment chf million related site closures costs reorganisation costs employee costs divestment net income earnings per share nutley site us completed second half resulted increase provisions environmental remediation ifrs net income increased chf terms cer diluted eps increased chf terms cer core net income increased core eps cer core basis excludes noncore items global restructuring costs global restructuring plans major items chf million pharmaceuticals division research development amortisation impairment goodwill intangible assets alliance business combination costs core eps increased strategic realignment chf million informatics mainly outsourcing functions shared service centres external excluding positive impact changes groups swiss pension plans providers details given note annual financial statements roche finance report roche finance report roche group financial review financial review roche group net income net debt chf billion decrease chf billion free cash flow chf billion largely used dividend payments chf billion net pension liability decreased chf billion due improved asset performance additional change change chf chf chf cer pension contributions offset impact lower discount rates regions net tax liabilities decreased ifrs net income main factors deferred tax effects impairment intangible assets decreased net pension liabilities equity compensation plans variable according price underlying equity reconciling items net tax global restructuring plans intangible asset amortisation free cash flow goodwill intangible asset impairment alliances business combinations free cash flow legal environmental cases change change major debt restructuring chf chf chf cer pension plan settlements pharmaceuticals normalisation equity compensation plan tax benefit diagnostics core net income corporate operating free cash flow supplementary net income eps information given pages includes calculations core eps reconciles treasury activities core results groups published ifrs results taxes paid free cash flow definition free cash flow detailed breakdown see pages financial position groups operating free cash flow remained strong chf billion decrease relative occurred growth financial position cash generation business offset higher capital expenditures increase net working capital higher investments intangible assets free cash flow chf billion decrease compared due lower operating free cash flow change change chf chf chf cer higher pension contributions group refined calculation free cash flow exclude dividends line peer pharmaceuticals group comparative free cash flow information restated accordingly impact operating free cash flow net working capital change longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating assets net debt pensions income taxes nonoperating assets net total net assets compared start year swiss franc depreciated significantly japanese yen also us dollar brazilian real resulted positive translation impact balance sheet positions positive us dollar translation impact net operating assets offset group level natural hedge groups us dollardenominated debt exchange rates used given pharmaceuticals division net working capital stable cer increase trade receivables line sales growth underlying inventory levels remained stable overall excluding final unwind esbriet inventory fair value adjustment increase inventories launch preparations offset inventory writedowns payables increased result conversion vendors extended payment terms longterm net operating assets lower mainly due amortisation due impairment one compound acquired part seragon acquisition diagnostics increase net working capital cer driven increase inventories due higher demand emerging markets preparation new launches trade receivables increased due sales growth asiapacific latin america regions payables increased since end result optimisation measures longterm net operating assets increased mainly due continued capital expenditure roche finance report roche finance report roche group financial review financial review roche group pharmaceuticals division operating results growth franchise resulted increased demand perjeta herceptin combination therapy continued uptake kadcyla sales increases immunology mainly came increasing use actemraroactemra europe us xolair esbriet sales us mabtherarituxan sales continued grow especially us china germany avastin sales pharmaceuticals division operating results stable lower us sales offset growth international region particularly china sales us notably mabthera rituxan herceptin negatively impacted increase reserves mandatory discounts hospitals b drug change change chf chf chf cer discount program ifrs results sales product sales royalties operating income cost sales pharmaceuticals division sales marketing distribution change sales sales research development chf chf cer general administration oncology operating profit avastin margin sales herceptin mabtherarituxan core results perjeta sales tarceva royalties operating income kadcyla cost sales xeloda marketing distribution gazyvagazyvaro research development others general administration total oncology core operating profit margin sales immunology actemraroactemra financial position xolair net working capital mabtherarituxan longterm net operating assets esbriet net operating assets cellcept pulmozyme free cash flow others operating free cash flow total immunology margin sales infectious diseases see pages definition core results core eps tamiflu valcytecymevene rocephin sales overview pegasys others pharmaceuticals division sales therapeutic area total infectious diseases change sales sales therapeutic area chf chf cer ophthalmology oncology lucentis immunology total ophthalmology infectious diseases ophthalmology neuroscience neuroscience madopar therapeutic areas others total sales total neuroscience pharmaceuticals division sales increased cer chf billion led growth oncology immunology products sales therapeutic areas growth primarily driven perjeta herceptin actemraroactemra mabtherarituxan esbriet xolair products together activasetnkase contributed chf billion cer sales growth sales pegasys tarceva lucentis declined total chf billion mircera competitive pressure sales valcytecymevene decreased due generic competition recently launched products neorecormonepogin alecensa tecentriq cotellic added chf billion sales others total therapeutic areas total sales total mabtherarituxan sales chf million chf million split oncology immunology franchises roche finance report roche finance report roche group financial review financial review roche group mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma fl rheumatoid avastin advanced colorectal breast lung kidney cervical ovarian cancer relapsed glioblastoma type brain tumour arthritis ra well certain types ancaassociated vasculitis avastin regional sales mabtherarituxan regional sales change sales sales chf chf cer change sales sales chf chf cer united states united states europe europe japan japan international international total sales total sales demand avastin continued robust sales remained stable overall us sales decreased result growing use sales higher driven primarily growth china us oncology immunology sales us new immunotherapy agents lung cancer setting europe sales stable growth came increasing treatment negatively impacted higher discounts hospitals b drug discount program sales europe increased ovarian colorectal lung cervical cancer sales negatively impacted delisting avastin uk france certain mainly coming sales growth germany france sales growth japan mainly due increase market share reflecting indications sales international region grew mainly driven increased market access china south korea approval additional dosage administration nonhodgkin lymphoma maintenance therapy well inflationary price increases argentina japan sales decreased due negative impact biannual government price cuts partially offset volume growth franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis herceptin regional sales actemraroactemra regional sales change sales sales change sales sales chf chf cer chf chf cer united states united states europe europe japan japan international international total sales total sales sales increased growth regions especially driven increased demand subcutaneous formulation perjeta regional sales represented total actemraroactemra sales monotherapy change sales sales chf chf cer xolair moderate severe persistent allergic asthma aa chronic idiopathic urticaria ciu united states europe xolair regional sales japan change sales sales international chf chf cer total sales united states total sales kadcyla regional sales us sales increased due higher prescriptions allergic asthma following new approval use children well continued uptake chronic idiopathic urticaria change sales sales chf chf cer united states lucentis wet agerelated macular degeneration wet amd macular oedema following retinal vein occlusion rvo diabetic europe macular oedema dme japan international lucentis regional sales total sales change sales sales chf chf cer overall growth franchise herceptin sales grew continued growth us resulting longer united states duration treatment combination perjeta early advanced breast cancer herceptin sales us also total sales negatively impacted b drug discount program europe herceptin sales continued grow especially uk germany demand herceptin international region mainly driven china perjeta sales increased sales lucentis declined due competition wet amd dme segments regions particularly europe us approved use surgery earlystage aggressive breast cancer kadcyla sales growth mainly driven international region well europe notably germany japan franchise grew overall especially kadcyla particular secondline treatment perjeta firstline treatment herpositive metastatic recurrent breast cancer roche finance report roche finance report roche group financial review financial review roche group tarceva advanced nonsmall cell lung nsclc pancreatic cancer europe sales growth due perjeta actemraroactemra mabtherarituxan herceptin growth partially offset continued price pressure across region sales germany grew led franchise avastin mabtherarituxan tarceva regional sales uk sales grew due governmental tamiflu order negatively impacted cancer drugs funds delisting avastin certain indications change sales sales chf chf cer united states japan sales grew despite government price cuts negative effect sales approximately growth europe driven tamiflu alecensa sales growth also came osteoporosis medicine edirol actemraroactemra japan franchise mabtherarituxan partially offset lower sales femara neutrogin oxarol international total sales international sales increased driven asiapacific latin america regions sales china grew due additional provincial reimbursements herceptin avastin mabtherarituxan sales growth south korea came increased sales sales lower declining sales us europe international region due increasing competitive pressure avastin franchise sales growth latin america driven part inflationary price increases argentina mexico sales decline mainly driven local loss exclusivity valcytecymevene xeloda sales growth turkey tnkaseactivase acute ischemic stroke ais acute myocardial infarction ami came franchise tnkaseactivase regional sales pharmaceuticals division sales e leading emerging markets change sales sales change sales sales chf chf cer country chf chf cer united states brazil international china total sales india mexico sales higher led growth us mainly driven updated prescribing information patients russia treated south korea turkey esbriet idiopathic pulmonary fibrosis ipf total sales esbriet regional sales change sales sales chf chf cer competition generic medicines biosimilars united states europe groups pharmaceutical products generally protected patent rights intended provide group exclusive international marketing rights various countries however patent rights varying scope duration group may required enter total sales costly litigation enforce patent intellectual property rights loss market exclusivity one major products either due patent expiration challenges generic medicines biosimilars noncomparable biologics reasons continued uptake esbriet us sales growth europe driven mainly spain italy could material adverse effect groups business results operations financial condition introduction generic biosimilar noncomparable biologic version similar medicine typically results significant reduction net sales pharmaceuticals division sales region relevant product manufacturers typically offer versions lower prices change sales sales region chf chf cer patents expiry always integral part groups business model future growth remain driven united states innovation latest information clinical studies included annual report pages details groups europe product development portfolio available download japan httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm international eemea product sales affected recent patent expiry latin america change asiapacific chf chf cer comment regions valcytecymevene us patent expiry major markets total sales recent approaching patent expiries us andor major markets pegasys tamiflu may impact eastern europe middle east africa sales products united states sales grew led new indications xolair growth recently launched products esbriet intellectual property biologics involve multiple patents patent timelines individual product therefore tecentriq alecensa franchise growth driven longer duration combination treatment herceptin difficult give exact date patent expiry biologic medicines group currently estimates basic primary perjeta sales lucentis fell due competitive pressure avastin sales decreased result growing use new patents major biologic medicines begin expire follows immunotherapy agents lung cancer setting addition tamiflu sales declined due weaker influenza season higher mabtherarituxan around mid us mandatory discounts hospitals b drug discount program affected mabtherarituxan herceptin sales particularly herceptin around us avastin around us around eu subcutaneous formulations mabtherarituxan herceptin beyond secondary patent rights roche finance report roche finance report roche group financial review financial review roche group patents mabtherarituxan herceptin eu expired based publicly available information competitor pharmaceuticals division research development companies group currently anticipates first biosimilar versions biologic medicines could come market europe change onwards still many uncertainties surrounding specific biosimilar versions groups biologic medicines chf chf cer approved us food drug administration research development core basis global restructuring plans amortisation intangible assets operating results impairment intangible assets total ifrs basis pharmaceuticals division royalties operating income core costs increased cer percentage sales increased compared oncology change chf chf cer franchise remained primary area research development notably cancer immunotherapy latestage development growth royalty income mainly oncology earlystage research development expenses increases related oncology immunology addition income outlicensing agreements pharmaceuticals division spent chf million chf million inlicensing pipeline compounds technologies income disposal products capitalised intangible assets global restructuring costs mainly came strategic realignment research total ifrs core basis development area significant impairment charges relate decision stop development one compound acquired part seragon acquisition following clinical data assessment delay development compound acquired part decrease cer due lower royalty income lower income outlicensing agreements royalty income fell trophos acquisition portfolio reassessment one compound due comparative period including certain significant royalty income addition certain patents expired royalty agreements partly offset increased sales third parties royaltybearing products decrease pharmaceuticals division general administration outlicensing income due income commercialisation mircera us collaboration partner change deblocking amendment income product disposals operating income increased due higher profitsharing income chf chf cer mainly result higher xolair sales europe also product divestment xenical administration pensions past service costs pharmaceuticals division cost sales gains losses disposal property plant equipment business taxes capital taxes change chf chf cer general items manufacturing cost goods sold period costs general administration core basis royalty expenses global restructuring plans collaboration profitsharing agreements impairment goodwill intangible assets impairment property plant equipment alliances business combinations cost sales core basis legal environmental cases global restructuring plans pensions settlement gains losses amortisation intangible assets total ifrs basis business combinations inventory fair value adjustment total ifrs basis core costs decreased cer percentage sales decreased mainly due income changes groups swiss pension plans first half excluding core costs increased impairment charge core costs increased cer percentage sales cost sales decreased percentage points manufacturing full writeoff goodwill anadys acquisition alliance business combination income came partial cost sales grew ahead sales growth pharmaceuticals division made considerable investments reversal contingent consideration provision seragon trophos acquisitions biologics manufacturing network recent years facilities come line leads certain increase costs especially rampup phases also temporary lower utilisation small molecules manufacturing site transformation period additionally external contract manufacturers used products give flexibility security supply chain roche pharmaceuticals chugai subdivisional operating results writedowns inventories also higher royalty expenses lower due expiry royaltybearing patents including avastin herceptin noncore costs include amortisation intangible assets mainly related intermune pharmaceuticals subdivisional operating results millions chf acquisition final unwind inventory fair value adjustment acquired esbriet inventories global restructuring costs roche pharmaceuticals mainly due manufacturing strategic realignment initiative announced pharmaceuticals chugai division pharmaceuticals division marketing distribution sales external customers change chf chf cer within division marketing distribution core basis core operating profit global restructuring plans margin sales external customers amortisation intangible assets operating profit total ifrs basis margin sales external customers operating free cash flow core costs increased cer percentage sales rose slightly costs incurred ensure margin sales increased patient access launches tecentriq ocrevus alecensa venclexta products restructuring costs relate pharmaceuticals division total core operating profit operating profit include elimination minus chf million unrealised intercompany gains productivity initiatives mainly asiapacific region roche pharmaceuticals chugai chf million roche finance report roche finance report roche group financial review financial review roche group increase exchange rate japanese yen positive impact approximately chugai results expressed free cash flow swiss francs japanese yen sales external customers chugai increased sales within division line chugai core operating profit decreased due lower gross profit sales within division lower milestone income pharmaceuticals division operating free cash flow higher research development costs partially offset higher gross profit sales external customers lower marketing change change distribution costs operating free cash flow chugai decreased due capital expenditure projects manufacturing chf chf chf cer research lower operating profit operating profit depreciation amortisation impairment financial position provisions equity compensation plans pharmaceuticals division net operating assets operating profit cash adjustments movement movement change change transactions cta chf chf chf cer chf chf operating profit net operating cash adjustments trade receivables increase decrease net working capital inventories investments property plant equipment trade payables investments intangible assets net trade working capital operating free cash flow receivablespayables sales net working capital definition free cash flow detailed breakdown see pages property plant equipment pharmaceuticals division generated operating free cash flow chf billion underlying cash generation remains strong goodwill intangible assets although shows decrease driven higher capital expenditure increasing net working capital higher investments provisions intangible assets new asset deals increase net working capital came inventories increased longterm assets net spending launch preparations trade receivables grew line sales positive impact longterm net operating assets operating free cash flow lower yearend balances main items capital expenditure driven projects switzerland germany us chugai described financial position section investments intangible assets include net operating assets inlicensing pipeline compounds technologies asset deals absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start year swiss franc depreciated significantly japanese yen also us dollar brazilian real resulting positive translation impact net operating assets exchange rates used given net working capital increase trade receivables line sales growth inventory levels overall remained stable compared end excluding final unwind chf million esbriet inventory fair value adjustment increase inventories launch preparations offset inventory writedowns payables increased since end result conversion vendors longer payment terms longterm net operating assets overall longterm net operating assets lower property plant equipment increased due manufacturing investments us switzerland germany chugai us site development continued switzerland basel kaiseraugst sites also south san francisco campus line sites master plans decrease intangible assets mainly due amortisation impairment one compound acquired part seragon acquisition provisions decreased due reversal contingent consideration provisions utilisation restructuring provisions mainly related restructuring divisions manufacturing network roche finance report roche finance report roche group financial review financial review roche group diagnostics division operating results centralised point care solutions increase sales business area major contributor divisional performance regions sales growth primarily driven immunodiagnostics business represents divisional sales also supported clinical chemistry business centralised point care solutions business diagnostics division operating results growing well asiapacific region due increased sales china growth europe middle east africa emea region mainly due immunodiagnostics change change chf chf chf cer ifrs results centralised point care solutions regional sales sales change sales sales royalties operating income chf chf cer cost sales europe middle east africa emea marketing distribution north america research development rest world general administration total sales operating profit margin sales diabetes care sales decreased primarily due fall north america sales major factors behind continued core results spill us medicare prices reductions commercial health plans well lower demand us reimbursement sales reductions canada blood glucose monitoring portfolio sales development emea mainly due decline uk royalties operating income germany middle east partially offset growth russia sales growth latin america due new tenders volume cost sales growth local inflationary effects marketing distribution research development diabetes care regional sales general administration change sales sales core operating profit chf chf cer margin sales europe middle east africa emea north america financial position rest world net working capital total sales longterm net operating assets net operating assets molecular diagnostics sales rose growth underlying molecular business well growth sequencing free cash flow business growth molecular business came virology business sales blood screening business also operating free cash flow increasing partly offset sales decline biochemical reagent business following outsourcing distribution third margin sales party sales sequencing business grew following ariosa kapa acquisitions completed regionally growth driven north america asiapacific see pages definition core results core eps molecular diagnostics regional sales change sales sales sales chf chf cer europe middle east africa emea sale diagnostics division continued increase growth cer chf billion centralised point care solutions north america formerly named professional diagnostics makes half divisions sales main contributor sales rest world growth led immunodiagnostics business molecular diagnostics sales increased increase underlying total sales molecular businesses well sales growth sequencing business ariosa kapa acquisitions completed diabetes care sales decreased due continued challenging market environment north america growth tissue diagnostics driven advanced staining product portfolio tissue diagnostics sales rose driven growth advanced staining portfolio companion diagnostics sales grew addition sales grew primary staining business due launch new instruments end diagnostics division sales business area regionally growth driven north america emea regions growth driven advanced staining portfolio sales asiapacific grew china main market change sales sales business area chf chf cer centralised point care solutions tissue diagnostics regional sales diabetes care change sales sales molecular diagnostics chf chf cer tissue diagnostics europe middle east africa emea total sales north america rest world total sales roche finance report roche finance report roche group financial review financial review roche group diagnostics division sales region diagnostics division marketing distribution change sales sales change region chf chf cer chf chf cer europe middle east africa emea marketing distribution core basis north america global restructuring plans asiapacific amortisation intangible assets latin america total ifrs basis japan total sales core costs increased cer primarily due increased spending asiapacific region mainly china north america also increased spend sequencing business core basis marketing distribution costs percentage sales emea region divisions largest market sales increases led centralised point care solutions molecular decreased compared global restructuring costs mainly reorganisation diabetes care diagnostics sales growth north america driven centralised point care solutions tissue diagnostics business partially offset decline diabetes care business impacted continued pricing pressure sales increase asiapacific mainly china resulting increasingly broadbased medical insurance coverage public demand diagnostics division research development latin america sales increased due new tender business local inflationary price increases sales growth japan change led centralised point care solutions business chf chf cer research development core basis diagnostics division sales e leading emerging markets global restructuring plans amortisation intangible assets change sales sales country chf chf cer total ifrs basis brazil china core costs increased cer driven spending genia ariosa acquisitions sequencing business india geneweave acquisition molecular diagnostics business key projects limelight platform harmony test cobas mexico vivodx system contributing increase percentage sales research development core costs increased russia south korea turkey diagnostics division general administration total sales change chf chf cer administration operating results pensions past service costs gains losses disposal property plant equipment diagnostics division royalties operating income business taxes capital taxes general items change chf chf cer general administration core basis royalty income global restructuring plans income outlicensing agreements alliances business combinations income disposal products legal environmental cases total ifrs core basis pensions settlement gains losses total ifrs basis decrease cer driven lower royalty income notably molecular diagnostics due base effect back royalty payments well expiry pcr technology patent core costs decreased cer due income swiss pension plan changes excluding core costs increased administration costs grew due sequencing business newly established affiliates diabetes care diagnostics division cost sales business business taxes decreased suspension medical device excise tax us income general items reflects underspending infrastructure areas percentage sales core costs decreased change chf chf cer manufacturing cost goods sold period costs royalty expenses cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis increase core costs came unfavourable product mix due higher instrument placements higher costs external suppliers core cost sales ratio increased compared global restructuring costs mainly related site closures initiatives harmonise processes systems roche finance report roche finance report roche group financial review financial review roche group financial position free cash flow diagnostics division net operating assets diagnostics division operating free cash flow change change movement movement chf chf chf cer change change transactions cta chf chf chf cer chf chf operating profit trade receivables inventories depreciation amortisation impairment trade payables provisions net trade working capital equity compensation plans receivablespayables net working capital operating profit cash adjustments property plant equipment operating profit net operating cash adjustments goodwill intangible assets increase decrease net working capital provisions investments property plant equipment longterm assets net investments intangible assets longterm net operating assets operating free cash flow sales net operating assets definition free cash flow detailed breakdown see pages absolute amount movement consolidated balances reported swiss francs split actual transactions translated average operating free cash flow diagnostics division chf million compared chf million cash generation rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow include cash movements full consolidated balance sheet given business measured operating profit net operating cash adjustments increased cer due improving annual financial statements reconciliation balance sheet information given operating results addition net working capital continued increase noted comments financial position increase significantly higher corresponding increase increased capital expenditure came expansion currency translation effects balance sheet amounts compared start year swiss franc depreciated manufacturing sites immunochemistry clinical chemistry products notably china germany us capital us dollar brazilian real resulting positive translation impact net operating assets diagnostics division projects indianapolis site manufacture reagents new generation diabetes care strips also significant net asset position japanese yen depreciation swiss franc japanese yen minor development divisions headquarters switzerland partially offset lower investments intangible assets compared impact exchange rates used given period factors combined give decrease divisions operating free cash flow relative net working capital net trade working capital increased cer trade receivables increased mainly due sales growth asiapacific latin america regions inventories increased due higher demand emerging markets due preparation new launches trade payables increased compared end result optimisation measures net liability receivablespayables increased due increased employee benefit accruals longterm net operating assets increase cer due increased property plant equipment decreased provisions offset lower intangible assets property plant equipment grew due instrument placements manufacturing site expansion china us germany well site infrastructure development germany us china switzerland provisions decreased following payment milestones related acquisitions decrease goodwill intangible assets mainly due amortisation roche finance report roche finance report roche group financial review financial review roche group corporate operating results foreign exchange impact operating results corporate operating results summary groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments change chf chf cer administration growth reported cer chf pensions past service costs change cer change chf business taxes capital taxes general items pharmaceuticals division general administration costs core basis sales global restructuring plans core operating profit alliances business combinations legal environmental cases diagnostics division total costs ifrs basis sales core operating profit financial position net working capital group longterm net operating assets sales net operating assets core operating profit free cash flow operating free cash flow exchange rates swiss franc see pages definition core results core eps general administration costs decreased cer core basis mainly due income changes groups december average december average swiss pension plans excluding core costs decreased increase legal environmental costs comes usd sale nutley site us change net operating assets due utilisation provisions environmental remediation eur activities nutley grenzach germany corporate operating free cash flow showed smaller outflow mainly due gain jpy proceeds nutley site compared swiss franc weaker number currencies particular japanese yen us dollar euro appreciation major currencies relevant group resulted total positive foreign exchange impact income statement compared negative impact sales developments resulted positive impact percentage point equivalent chf billion currency translation gain operating profit percentage point mainly appreciation japanese yen us dollar sensitivity group sales core operating profit change average foreign currency exchange rates swiss franc shown table currency sensitivities impact change average exchange rate sales core operating profit versus swiss franc chf chf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro costs sales marketing also administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs mainly concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany chugais revenues costs denominated japanese yen roche finance report roche finance report roche group financial review financial review roche group treasury taxation results financial income expense financial income expense net income chf million compared net expense chf million net income treasury taxation results equity securities chf million chf million comparative period net foreign exchange results reflect hedging costs losses unhedged positions net foreign exchange losses chf million compared net losses change change chf chf chf cer chf million results included foreign exchange losses chf million venezuela chf million ifrs results argentina full analysis financial income expense given note annual financial statements operating profit financing costs financial income expense income taxes profit taxes income taxes groups effective tax rate compared ifrs basis compared core basis net income largely due deferred tax impact resulting tax rate changes ifrs results include noncore income attributable release contingent consideration provisions taxable hence net tax effect alliances business roche shareholders combinations line table positive impact mostly offset unfavourable deferred tax impact equity noncontrolling interests compensation plans core results analysis groups effective tax rate operating profit financing costs profit income profit income financial income expense tax taxes tax rate tax taxes tax rate profit taxes chf chf chf chf income taxes groups effective tax rate core basis net income global restructuring plans attributable goodwill intangible assets roche shareholders alliances business combinations noncontrolling interests legal environmental cases major debt restructuring financial position treasury taxation normalisation equity compensation plan tax benefit net debt pensions groups effective tax rate ifrs basis income taxes financial noncurrent assets derivatives net collateral net financial position interest payable nonoperating assets net net debt decreased chf billion free cash flow larger dividends paid transactions equity instruments total net assets liabilities net pension liabilities decreased chf billion due improved asset performance additional pension contributions offset lower discount rates regions net tax liabilities decreased mainly due deferred tax impact free cash flow treasury taxation impairment intangible assets partially offset deferred tax effects decreased net pension liabilities deferred tax treasury activities effects equity compensation plans variable according price underlying equity december group taxes paid held financial longterm assets market value chf billion consist mostly holdings biotechnology total pharmaceuticals companies acquired part licensing transactions scientific collaborations compared start year swiss franc depreciated us dollar negative translation impact groups us dollardenominated debt see pages definition core results core eps group refined calculation free cash flow exclude dividends line peer group free cash flow restated accordingly free cash flow financing costs cash outflow treasury activities increased chf billion due additional pension contributions switzerland us financing costs lower ifrs basis due loss comparative period chf million major debt ireland due strategic investments partly offset lower interest payments total taxes paid stable chf billion restructuring core financing costs chf billion decrease cer compared interest expenses including group refined calculation free cash flow exclude dividends line peer group free cash flow amortisation debt discounts issue costs decreased chf million due continued repayment refinancing restated accordingly debt leading lower weighted average cost debt loss early redemption debt chf million compared chf million net interest cost defined benefit pension plans increased cer chf million due higher discount rates us germany end full analysis financing costs given note annual financial statements details debt repayments redemptions given note roche finance report roche finance report roche group financial review financial review roche group cash flows net debt net debt millions chf operating free cash flow billions chf free cash flow billions chf january cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow free cash flow millions chf dividend payments transactions equity instruments pharmaceuticals diagnostics corporate group business combinations net divestments subsidiaries hedging collateral arrangements operating profit ifrs basis currency translation fair value movements operating profit cash adjustments change net debt operating profit net operating cash adjustments increase decrease net working capital december investments property plant equipment cash cash equivalents investments intangible assets marketable securities operating free cash flow longterm debt treasury activities shortterm debt taxes paid net debt end period free cash flow definition net debt see operating profit ifrs basis operating profit cash adjustments net debt currency profile millions chf operating profit net operating cash adjustments cash marketable securities debt increase decrease net working capital investments property plant equipment us dollar investments intangible assets euro operating free cash flow swiss franc treasury activities japanese yen taxes paid pound sterling free cash flow total definition free cash flow detailed breakdown see pages group refined calculation free cash flow exclude dividends line peer group free cash flow restated accordingly us dollardenominated debt includes bonds notes denominated euros swapped us dollars therefore consolidated results economic characteristics equivalent us dollardenominated bonds notes operating free cash flow decreased cer chf billion underlying cash generated operations increased chf billion offset higher capital expenditure increase net working capital higher investments intangible net debt position group december chf billion decrease chf billion december assets free cash flow largely used annual dividend payment chf billion cash outflow treasury activities increased chf billion due higher pension contributions investments financial issuance redemption repurchase bonds notes see note annual financial statements longterm assets partly offset lower interest payments taxes paid stable chf billion free cash flow chf billion impact liquid funds impact net debt position lower due lower operating free cash flow higher pension contributions group refined calculation free cash flow exclude dividends line peer group free cash flow restated accordingly resulting increase chf million free cash flow period impact operating free cash flow change roche finance report roche finance report roche group financial review financial review roche group contractual obligations commitments pensions postemployment benefits group obligations commitments set table carrying values shown consolidated balance postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate sheet potential obligations shown discounted risk adjusted foreign currency denominated amounts fund thirdparty financial institution legal constructive obligation pay contributions translated swiss francs december exchange rates expenses groups defined contribution plans chf million chf million plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising plans usually contractual obligations commitments december millions chf established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources potential obligation undiscounted less carrying year years years years total value onbalance sheet defined benefit plans debt bonds notes operating income chf million recorded past service costs changes groups pension plans debt switzerland represents impact adjustment pension liability plan changes excluding expenses contingent consideration provisions groups defined benefit plans chf million chf million based revised actuarial assumptions end accounts payable expenses groups defined benefit plans expected approximately chf million driven lower discount derivative financial instruments rates beginning estimates pension expenses include settlement past servicecurtailment unfunded defined benefit plans effects might arise year total onbalance sheet commitments funding status balance sheet position offbalance sheet capital commitments property plant equipment chf chf operating leases funded plans contract manufacturing commitments fair value plan assets alliance collaboration commitments defined benefit obligation total offbalance sheet commitments funding total contractual commitments unfunded plans defined benefit obligation references notes consolidated financial statements total funding status debt consists mainly bonds notes includes principal interest groups debt instruments debt mainly commercial paper carrying values discounted based interest rates inherent instruments limit asset recognition reimbursement rights contingent consideration provisions potential payments arising business combinations carrying values risk net recognised asset liability adjusted discounted overall funding status ifrs basis groups funded defined benefit plans increased compared start unfunded defined benefit plans mainly pension plans groups german affiliates fully reserved pension year plan assets increased chf billion mainly driven higher returns assets additional contributions paid obligations invested local affiliates operations carrying values discounted future company contributions groups pension plans switzerland us ireland increase defined benefit obligation arising decrease groups funded plans shown table discount rates regions since end mostly offset changes groups swiss plans decreased defined benefit obligation chf million funded status pension funds monitored local pension fund governance bodies capital commitments property plant equipment noncancellable commitments purchase construction well closely reviewed group level additional contributions paid groups pension plans mainly roche sites basel switzerland mannheim germany south san francisco us also chugai sites switzerland us ireland total cash outflow groups defined benefit plans chf million compared chf million operating leases future obligations noncancellable lease contracts group implement ifrs leases point obligations reported balance sheet unfunded plans mainly groups german affiliates fully reserved pension obligations invested local affiliates operations unfunded liabilities plans increased chf billion due decrease contract manufacturing commitments future minimum takeorpay commitments purchase inventories arising discount rate germany groups major longterm agreements external contract manufacturing organisations cmos full details groups pensions postemployment benefits given note annual financial statements alliance collaboration commitments potential upfront milestone payments may become due groups inlicensing arrangements potential payments alliance partners asset deals within next three years included assuming projects currently development successful payments beyond three year time included asset deals provisions legal environmental matters included table timing amount cash outflow uncertain contingent development matters question roche finance report roche finance report roche group financial review financial review roche group roche shares information per share nonvoting equity security change chf chf chf share price market capitalisation december eps basic eps diluted change chf core eps basic share price chf core eps diluted nonvoting equity security genussschein price chf equity attributable roche shareholders per share market capitalisation billions chf dividend per share roche ranked number among peer group consisting roche healthcare companies total shareholder details please refer notes annual financial statements payout ratio calculated return tsr defined share price growth plus dividends measured swiss francs actual exchange rates constant exchange dividend per share divided core earnings per share rates cer roche ranked number yearend return minus roche shares minus roche nonvoting equity securities combined performance share nonvoting equity security minus compared weighted average return peer group chf terms cer debt healthcare sector underperformed key markets specific investor concerns around pricing pressure us pricing reforms elections swiss market index also underperformed relative major global indices investors reduced exchange rate exposure swiss equities driven strengthening us dollar context despite positive news flow year strong late stage pipeline roche shares overshadowed anticipation key trial readout expected early debt redemptions following redemptions uncertainty impact biosimilars early partial redemption usd million notes originally due march redeemed march following exercise earlycall option december peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck co novartis pfizer redemption due date march eur billion notes roche sanofi takeda early redemption usd million notes originally due march redeemed august following exercise earlycall option june total shareholder return development addition december group completed tender offer repurchase usd million fixed rate notes due march dec mar june sept dec debt issuances following issuances february group issued eur million notes due february march group issued usd billion notes due may october group issued usd million notes due january usd million notes due january transactions described note annual financial statements roche share roche nonvoting equity security peer set index maturity schedule groups bonds notes outstanding december shown table bonds notes nominal amounts december contractual maturity source datastream data roche peer index rebased january peer index converted swiss francs daily actual exchange rates currency fluctuations influence representation relative performance roche versus peer index us dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf proposed dividend board directors proposing increase dividend chf per share nonvoting equity security beyond chf approval annual general meeting th consecutive increase dividend dividend total proposal approved shareholders dividend payments total shares nonvoting equity securities amount chf billion total translated december exchange rates chf billion resulting payout ratio based core net income based prices yearend proceeds bonds notes eur billion swapped us dollars therefore consolidated results bonds notes economic dividend yield roche share yield nonvoting equity security characteristics equivalent us dollardenominated bonds notes information roche securities given pages roche finance report roche finance report roche group financial review financial review roche group group plans meet debt obligations using existing liquid funds well cash generated business operations group enjoys strong longterm investmentgrade credit ratings aa standard poors moodys time free cash flow chf billion included cash generated operations well payment interest tax short roche rated highest available shortterm ratings agencies event financing requirements ratings overall term financing requirements group commercial paper programme us issue usd billion creditworthiness roche group permit efficient access international capital markets including commercial paper unsecured commercial paper notes committed credit lines usd billion available backstop lines commercial paper market group committed credit lines various financial institutions totalling chf billion chf billion serve notes totalling usd billion outstanding december december usd billion longerterm financing backstop lines commercial paper programme december debt drawn credit lines group maintains strong longterm investmentgrade credit ratings aa standard poors moodys facilitate efficient access international capital markets market risk market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var information groups debt given note annual financial statements assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices groups var increased mainly due gradual credit ratings roche group december increase longterm interest rates major economies shortterm longterm outlook interest rate risk interest rate risk arises movements interest rates could affect group financial result value moodys p stable group equity group may use interest rate derivatives manage interestraterelated exposure financial result standard poors aa stable information financial risk management financial risks var methodology included note annual financial statements financial risks international financial reporting standards december group net debt position chf billion chf billion financial assets group managed conservative way objective meet groups financial obligations times roche group using international financial reporting standards ifrs report consolidated results since group implemented various minor amendments existing standards interpretations material impact asset allocation considerable portion cash marketable securities group currently holds used debt groups overall results financial position redemptions liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements group currently assessing potential impacts various new revised standards interpretations mandatory january group yet applied based analysis date group anticipate cash marketable securities material impact groups overall results financial position chf total chf total group also assessing new revised standards mandatory summarised see note cash cash equivalents annual financial statements details money market instruments debt securities ifrs financial instruments group plans implement new standard effective january group currently equity securities anticipate comparative results restated new standard applied standard deals classification total cash marketable securities recognition measurement including impairment financial instruments impairment financial assets including trade lease receivables also introduces new hedge accounting model credit risk credit risk arises possibility counterparties transactions may default obligations causing financial ifrs revenues contracts customers group plans implement new standard effective january losses group rating profile groups chf billion cash fixed income marketable securities remained strong group anticipate new standard change amounts revenue recognised therefore invested aaaa range group signed netting collateral agreements counterparties order restatement necessary new standard contains new set principles recognise measure mitigate counterparty risk derivative positions revenue well new requirements related presentation core principle framework revenue recognised dependent transfer promised goods services customer amount reflects consideration group trade receivables chf billion since beginning financial difficulties southern european received exchange goods services countries notably spain italy greece portugal group leading supplier healthcare sectors countries december trade receivables eur billion chf billion public customers countries decrease ifrs leases group plans implement new standard effective january apply cumulative catchup compared december euro terms due substantial collections late group uses different measures method option transition meaning comparative results restated new standard applied improve collections countries including intense communication customers forfaiting negotiations payment plans main impact new standard bring operating leases onbalance sheet group assessing potential impact charging interest late payments legal actions strict commercial policies place selected hospitals greece italy currently anticipates new standard result carrying value property plant equipment increased accounts hospitals spain portugal closely monitored since groups trade receivables balance southern least chf billion debt increased similar amount date implementation application new standard europe decreased eur terms result part currently reported operating lease costs recorded interest expenses given leases involved prevailing low interest rate environment group currently expect effect material liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group good cash generation ability future cash flows used repay debt instruments coming years roche finance report roche finance report roche group roche group consolidated financial statements roche group consolidated financial statements roche group roche group roche group consolidated income statement year ended december millions chf consolidated financial statements pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development roche group consolidated income statement year ended december millions chf general administration operating profit pharmaceuticals diagnostics corporate group sales financing costs royalties operating income financial income expense cost sales profit taxes marketing distribution research development income taxes general administration net income operating profit attributable financing costs roche shareholders financial income expense noncontrolling interests profit taxes earnings per share nonvoting equity security income taxes basic chf net income diluted chf attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche finance report roche group roche group consolidated financial statements roche group consolidated financial statements roche group roche group consolidated statement comprehensive income millions chf roche group consolidated balance sheet millions chf year ended december december december december net income recognised income statement noncurrent assets property plant equipment comprehensive income goodwill remeasurements defined benefit plans intangible assets items never reclassified income statement deferred tax assets defined benefit plan assets availableforsale investments noncurrent assets cash flow hedges total noncurrent assets currency translation foreign operations items may reclassified income statement current assets inventories comprehensive income net tax accounts receivable current income tax assets total comprehensive income current assets marketable securities attributable cash cash equivalents roche shareholders total current assets noncontrolling interests total total assets noncurrent liabilities longterm debt deferred tax liabilities defined benefit plan liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity roche finance report roche finance report roche group roche group consolidated financial statements roche group consolidated financial statements roche group roche group consolidated statement cash flows millions chf roche group consolidated statement changes equity millions chf year ended december non share retained fair value hedging translation controlling total cash flows operating activities capital earnings reserves reserves reserves total interests equity cash generated operations year ended december increase decrease net working capital january payments made defined benefit plans utilisation provisions net income recognised income statement disposal products availableforsale investments operating cash flows cash flow hedges cash flows operating activities income taxes paid currency translation foreign operations income taxes paid remeasurements defined benefit plans total cash flows operating activities total comprehensive income cash flows investing activities dividends purchase property plant equipment equity compensation plans net transactions purchase intangible assets equity disposal property plant equipment business combinations disposal intangible assets changes noncontrolling interests business combinations equity contribution noncontrolling interests divestment subsidiaries december interest dividends received sales marketable securities year ended december purchases marketable securities january investing cash flows total cash flows investing activities net income recognised income statement availableforsale investments cash flows financing activities cash flow hedges proceeds issue bonds notes currency translation foreign operations redemption repurchase bonds notes remeasurements defined benefit plans increase decrease commercial paper total comprehensive income increase decrease debt hedging collateral arrangements dividends changes noncontrolling interests equity compensation plans net transactions equity contribution noncontrolling interests equity interest paid changes noncontrolling interests dividends paid december equitysettled equity compensation plans net transactions equity financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group notes roche group impairment december group chf million property plant equipment see note chf million goodwill see note chf million intangible assets see note goodwill intangible assets yet available consolidated financial statements use reviewed annually impairment property plant equipment intangible assets use assessed impairment triggering event provides evidence asset may impaired assess whether impairment exists estimates expected future cash flows used actual outcomes could vary significantly estimates factors changes discount rates planned use buildings machinery equipment closure facilities presence competition technical obsolescence lower anticipated product sales could lead shorter useful lives impairment general accounting principles pensions postemployment benefits group operates number defined benefit plans fair values recognised plan assets liabilities based upon statistical actuarial calculations measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate basis preparation assumptions december present value groups defined benefit obligation chf million see note actuarial assumptions used may differ materially actual results due changes market economic conditions longer consolidated financial statements hereafter annual financial statements roche group prepared shorter life spans participants changes factors assessed differences could impact defined accordance international financial reporting standards ifrs comply swiss law prepared using benefit plan assets liabilities recognised balance sheet future periods historical cost convention except items required accounted fair value approved issue board directors january subject approval annual general meeting shareholders march legal provisions group provides anticipated legal settlement costs probable outflow resources reliably estimated december group chf million legal provisions status significant legal cases financial statements annual financial statements roche holding ltd company registered switzerland disclosed note estimates consider specific circumstances legal case relevant legal advice inherently subsidiaries group judgemental due highly complex nature legal cases estimates could change substantially time new facts emerge legal case progresses reliable estimate made provision recorded contingent liabilities disclosed groups significant accounting policies changes accounting policies disclosed note material environmental provisions group provides anticipated environmental remediation costs probable outflow key accounting judgements estimates assumptions resources reasonably estimated december group chf million environmental provisions see note environmental provisions consist primarily costs fully clean refurbish contaminated sites including landfills preparation annual financial statements requires management make judgements estimates assumptions affect treat contain contamination certain sites estimates inherently judgemental due uncertainties related reported amounts revenues expenses assets liabilities contingent amounts actual outcomes could differ detection previously unknown contamination method extent remediation percentage problematic management estimates estimates underlying assumptions reviewed ongoing basis based historical materials attributable group remediation sites financial capabilities potentially responsible parties experience various factors revisions estimates recognised period estimate revised following estimates could change substantially time new facts emerge environmental remediation progresses considered key accounting judgements estimates assumptions made believed appropriate based upon currently available information contingent consideration provisions group makes provision estimated fair value contingent consideration arrangements arising business combinations december group chf million contingent consideration provisions revenue nature groups business many sales transactions simple structure may consist see note total potential payments contingent consideration arrangements business combinations could multiple components occurring different times group also party outlicensing agreements involve upfront milestone chf million see note estimated amounts provided expected payments determined considering possible payments occurring several years may also involve certain future obligations revenue recognised scenarios forecast sales performance criteria amount paid scenario probability managements judgement significant risks rewards ownership transferred group retain scenario discounted net present value estimates could change substantially time new facts emerge continuing managerial involvement effective control goods sold obligation fulfilled transactions scenario develops result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement may circumstances level sales income taxes december group current income tax net liability chf million deferred tax net asset returns hence revenues reliably measured cases sales recognised right return expires chf million see note significant estimates required determine current deferred tax assets liabilities generally upon prescription products patients order estimate management uses publicly available information estimates based interpretations existing tax laws regulations tax positions uncertain accruals prescriptions well information provided wholesalers intermediaries recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience factors may impact current deferred taxes include changes revenues product sales recorded net allowances estimated rebates chargebacks cash discounts estimates product tax laws regulations rates changing interpretations existing tax laws regulations future levels research development returns established time sale product sales allowances based estimates amounts earned spending changes pretax earnings claimed related sales december group chf million provisions accruals expected sales returns chargebacks rebates including medicaid us similar rebates countries provisions accruals relating leases treatment leasing transactions mainly determined whether lease considered operating finance us pharmaceuticals business amounted chf million chf million associated expected sales returns lease making assessment management looks substance lease well legal form makes judgement estimates take consideration historical experience current contractual statutory requirements specific known market events whether substantially risks rewards ownership transferred arrangements take legal form trends competitive pricing new product introductions estimated inventory levels shelf life products actual lease nevertheless convey right use asset also covered assessments future results vary estimates need adjusted could effect sales earnings period adjustment december group chf million provisions doubtful receivables see note estimates based consolidation group periodically undertakes transactions may involve obtaining control significant influence analyses ageing customer balances specific credit circumstances historical trends groups experience taking also companies transactions include equity acquisitions asset purchases alliance agreements cases management account current economic conditions makes assessment whether group control significant influence company whether consolidated subsidiary accounted associated company making assessment management considers business combinations group initially recognises fair value identifiable assets acquired liabilities assumed non underlying economic substance transaction addition contractual terms controlling interest consideration transferred business combination management judgement particularly involved recognition fair value measurement intellectual property inventories contingent liabilities contingent consideration making assessment management considers underlying economic substance items concerned addition contractual terms roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group operating segment information pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription revenues external customers pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sales sale licensing products technology third parties residual operating activities divested businesses certain global royalties operating income activities reported corporate include corporate executive committee global group functions communications total human resources finance including treasury taxes pension fund management legal safety environmental services sub divisional information roche pharmaceuticals chugai operating segments within pharmaceuticals division also presented revenues operating segments sales divisional information millions chf royalties operating income elimination income within division pharmaceuticals diagnostics corporate group total revenues external customers sales segment results royalties operating income operating profit total elimination results within division operating profit revenues operating segments sales capital expenditure royalties operating income business combinations elimination interdivisional revenue additions property plant equipment total additions intangible assets total segment results operating profit research development research development costs capital expenditure elimination costs within division business combinations total additions property plant equipment additions intangible assets segment information total depreciation property plant equipment amortisation intangible assets research development impairment property plant equipment research development costs impairment goodwill impairment intangible assets segment information inventory fair value adjustment depreciation property plant equipment equity compensation plan expenses amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets net operating assets millions chf inventory fair value adjustment assets liabilities net assets equity compensation plan expenses pharmaceuticals diagnostics corporate total operating nonoperating group roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group net operating assets pharmaceuticals subdivisional information millions chf major customers assets liabilities net assets total three us national wholesale distributors represent quarter groups revenues three us national roche pharmaceuticals wholesale distributors amerisourcebergen corp chf billion chf billion mckesson corp chf billion chugai chf billion cardinal health inc chf billion chf billion approximately revenues elimination within division pharmaceuticals operating segment residual diagnostics segment pharmaceuticals division supplementary revenues information information geographical area millions chf revenues product sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts revenues external customers noncurrent assets earned claimed related sales estimates take consideration historical experience current contractual royalties property plant goodwill sales operating income equipment intangible assets statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted could switzerland effect sales earnings period adjustment germany rest europe grosstonet sales reconciliation pharmaceuticals division shown table companies diagnostics europe division similar reconciling items much lower amounts united states pharmaceuticals division sales grosstonet reconciliation millions chf rest north america north america gross sales latin america government regulatory mandatory price reductions contractual price reductions japan cash discounts rest asia customer returns reserves asia others net sales africa australia oceania total government regulatory mandatory price reductions consist mandatory price reductions major elements b drug discount program medicaid plans us totalled usd billion equivalent chf billion usd billion equivalent chf billion switzerland germany contractual price reductions include rebates chargebacks result contractual agreements primarily rest europe volumebased performancebased europe cash discounts include credits offered wholesalers remitting payment purchases within contractually defined united states incentive periods rest north america north america customer returns reserves allowances established expected product returns latin america sales reductions expected withheld customer upon settlement contractual price reductions cash discounts recorded balance sheet deduction trade receivables see note sales reductions separately japan payable customers governmental health authorities healthcare regulatory authorities recorded balance sheet accrued rest asia liabilities see note provisions sales returns recorded balance sheet provisions see note asia revenues royalties operating income millions chf africa australia oceania total royalty income supplementary unaudited information sales therapeutic areas pharmaceuticals division business areas income outlicensing agreements diagnostics division given financial review sales allocated geographical areas destination according location income disposal products customer royalties operating income allocated according location group company receives total royalty operating income revenue income product disposals operating income included product divestment xenical income outlicensing arrangements included upfront milestone payments exclusive licence agreement galenica commercialisation mircera us payment collaboration partner deblocking amendment roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group net financial expense income taxes financing costs millions chf income tax expenses millions chf interest expense current income taxes amortisation debt discount deferred taxes net gains losses debt derivatives total income tax expense net gains losses redemption repurchase bonds notes loss major debt restructuring since group operates internationally subject income taxes many different tax jurisdictions group calculates average discount unwind expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year net interest cost defined benefit plans year due changes mix groups taxable income changes local tax rates total financing costs groups average expected tax rate decreased main drivers decrease lower local tax rate japan lower proportion groups profits coming tax jurisdictions higher local tax rates average group tax rate financial income expense millions chf groups effective tax rate increased main drivers increase deferred tax impact tax rate changes various countries deferred tax impact respect equity compensation plans varies according net gains losses sale equity securities price underlying equity partially offset favourable impact release contingent consideration net gains losses equity security derivatives provisions taxable dividend income writedowns impairments equity securities groups effective tax rate reconciled groups average expected tax rate follows net income equity securities reconciliation groups effective tax rate interest income net gains losses sale debt securities net interest income income debt securities average expected tax rate net foreign exchange gains losses tax effect net gains losses foreign currency derivatives nontaxable incomenondeductible expenses foreign exchange gains losses equity compensation plans research development tax credits manufacturing deductions net financial income expense us state tax impacts tax unremitted earnings associates utilisation previously unrecognised tax losses deferred tax intragroup transfers total financial income expense prior year differences groups effective tax rate income tax benefit recorded respect equity compensation plans varies according price underlying equity net financial expense millions chf chf million chf million income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefit approximately chf million chf million would recorded financing costs tax effects comprehensive income millions chf financial income expense net financial expense pretax aftertax pretax aftertax amount tax amount amount tax amount financial result treasury management remeasurements defined benefit plans financial result pension management availableforsale investments associates cash flow hedges net financial expense currency translation foreign operations comprehensive income roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group income tax assets liabilities millions chf deferred tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows current income taxes unrecognised tax losses expiry assets liabilities amount applicable amount applicable net current income tax assets liabilities chf tax rate chf tax rate within one year deferred taxes one five years assets five years liabilities total unrecognised tax losses net deferred tax assets liabilities five years category includes losses used us state income tax purposes states current income tax liabilities include accruals uncertain tax positions permit tax reporting separate entity basis current income taxes movements recognised net assets liabilities millions chf deferred tax liabilities established withholding tax taxes would payable remittance earnings foreign subsidiaries amounts currently regarded permanently reinvested total unremitted earnings group regarded permanently reinvested chf billion december chf billion net current income tax asset liability january income taxes paid business combinations charged credited income statement charged credited equity equity compensation plans transactions shareholders currency translation effects movements net current income tax asset liability december deferred taxes movements recognised net assets liabilities millions chf property plant intangible defined temporary equipment assets benefit plans differences total year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december year ended december january charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december deferred tax net assets temporary differences mainly relate accrued liabilities provisions unrealised profit inventory roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group business combinations identifiable assets acquired liabilities assumed set table pharmaceuticals acquisitions net assets acquired millions chf acquisitions trophos fmi total group complete business combinations intangible assets product intangibles use product intangibles available use acquisitions cash cash equivalents deferred tax liabilities acquisitions net assets acquired millions chf net assets liabilities net identifiable assets pharmaceuticals diagnostics total noncontrolling interests intangible assets fair value previously held equity interest product intangibles use goodwill allocated foundation medicine product intangibles available use goodwill allocated roche pharmaceuticals marketing intangibles use total consideration cash cash equivalents deferred tax liabilities cash net assets liabilities contingent consideration net identifiable assets total consideration noncontrolling interests fair value previously held equity interest fair value intangible assets determined using excess earning method based management forecasts goodwill observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted total consideration discount rate trophos fmi valuations performed independent valuers cash trophos goodwill represents control premium acquired work force synergies expected integrating contingent consideration acquired company groups existing business none goodwill expected deductible income tax purposes total consideration fmi goodwill represents strategic value roche pharmaceuticals accessing fmis molecular information genomic analysis also represents premium paid traded market price obtain control business acquired workforce pharmaceuticals expected synergies none goodwill expected deductible income tax purposes noncontrolling interests fmi measured date acquisition proportionate share fmis identifiable net assets trophos march group acquired controlling interest trophos privately owned company based marseille france trophos reported pharmaceuticals division total consideration eur million eur million group recognised financial gain chf million fair valuing equity interest fmi held group prior paid cash eur million arose contingent consideration arrangement contingent payments based transaction gain included financial income expense achievement performancerelated milestones range undiscounted outcomes zero eur million impairment chf million recorded intangible assets acquired trophos acquisition see note directly attributable transaction costs chf million reported pharmaceuticals operating segment within general administration expenses mainly relate fmi acquisition foundation medicine inc april group acquired controlling interest foundation medicine inc fmi publicly owned us company based cambridge massachusetts fmi listed nasdaq stock code fmi fmi reported impact trophos fmi acquisitions results pharmaceuticals division group material pharmaceuticals division total cash consideration usd billion diagnostics ariosa diagnostics inc january group acquired controlling interest ariosa diagnostics inc ariosa us privately owned company based san jose california ariosa reported diagnostics operating segment part sequencing business total consideration usd million usd million paid cash usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd million signature diagnostics ag february group acquired controlling interest signature diagnostics ag signature privately owned company based potsdam germany signature reported diagnostics operating segment part sequencing business total cash consideration eur million capp medical inc april group acquired controlling interest capp medical inc capp us privately owned company based palo alto california capp reported diagnostics operating segment part sequencing business total consideration usd million usd million paid cash usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd million roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group global restructuring plans geneweave biosciences inc august group acquired controlling interest geneweave biosciences inc geneweave us privately owned company based los gatos california geneweave reported diagnostics operating segment part molecular diagnostics business total consideration usd million usd million paid cash usd million arose contingent consideration arrangement contingent payments based group continued implementation several major global restructuring plans initiated prior years notably achievement performancerelated milestones range undiscounted outcomes zero usd million strategic realignment pharmaceuticals divisions manufacturing network programmes address longterm strategy diagnostics division kapa biosystems inc november group acquired controlling interest kapa biosystems inc kapa us privately owned company based wilmington massachusetts kapa reported diagnostics operating segment part global restructuring plans costs incurred millions chf sequencing business total cash consideration usd million diagnostics site consolidation plans total identifiable assets acquired liabilities assumed set table year ended december global restructuring costs diagnostics acquisitions net assets acquired millions chf employeerelated costs site closure costs ariosa signature capp geneweave kapa total reorganisation expenses intangible assets total global restructuring costs product intangibles use product intangibles available use additional costs marketing intangibles use impairment goodwill cash cash equivalents impairment intangible assets deferred tax liabilities legal environmental cases net assets liabilities net identifiable assets total costs goodwill total consideration year ended december global restructuring costs cash employeerelated costs contingent consideration site closure costs total consideration divestment products businesses reorganisation expenses fair value intangible assets determined using excess earning method based management forecasts total global restructuring costs observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate ariosa capp geneweave kapa valuations ariosa capp geneweave additional costs kapa performed independent valuers impairment goodwill impairment intangible assets goodwill represents control premium acquired work force synergies expected integrating acquired legal environmental cases companies groups existing business none goodwill expected deductible income tax purposes total costs directly attributable transaction costs chf million reported diagnostics operating segment within general includes diabetes care autonomy speed restructuring plan administration expenses includes pharmaceuticals division strategic realignment manufacturing network includes plans pharmaceuticals division research development strategic realignment outsourcing impact ariosa signature capp geneweave kapa acquisitions results diagnostics division group material diagnostics division cash flows business combinations costs roche diabetes care autonomy speed initiative chf million chf million mainly consultancy itrelated matters well employeerelated costs new strategy plans diagnostics diabetes care incurred acquisitions net cash outflow millions chf costs chf million related site closures employees spending smaller plans within division chf million included costs related certain projects pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid deferred consideration paid contingent consideration paid cash acquired company transaction costs total net cash outflow roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group site consolidation global restructuring plans classification costs millions chf november pharmaceuticals division announced strategic realignment manufacturing network including exiting depreciation depreciation manufacturing sites clarecastle ireland legans spain segrate italy florence us costs plan amortisation amortisation chf million chf million chf million noncash writedowns accelerated depreciation property impairment costs total impairment costs total plant equipment chf million chf million related site closures costs employee costs cost sales reorganisation expenses divestment nutley site us completed second half resulted pharmaceuticals increase provisions environmental remediation see note diagnostics marketing distribution pharmaceuticals global restructuring plans diagnostics research development total costs chf million major items chf million pharmaceuticals division research pharmaceuticals development strategic realignment chf million informatics mainly outsourcing functions shared service centres diagnostics external providers remaining minor plans totalled chf million general administration pharmaceuticals total costs chf million major items chf million pharmaceuticals division research diagnostics development strategic realignment chf million various initiatives reduce field force europe asiapacific corporate regions part realignment april group sold wholly owned subsidiary marcadia biotech inc third party total loss disposal chf million remaining minor plans totalled chf million total operating segment global restructuring plans summary costs incurred millions chf roche pharmaceuticals chugai diagnostics employeerelated costs corporate termination costs total defined benefit plans employeerelated costs total employeerelated costs site closure costs impairment property plant equipment accelerated depreciation property plant equipment gains losses disposal property plant equipment site closure costs total site closure costs loss divestment subsidiary total costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group property plant equipment divestment nutley site september group completed divestment nutley site third party part previously announced property plant equipment movements carrying value assets millions chf restructuring total net consideration received cash chf million part divestment expected costs environmental remediation reassessed accordingly environmental provisions increased chf million see note buildings land machinery construction land improvements equipment progress total january genentech property purchase option exercise cost accumulated depreciation impairment genentech entered master lease agreement mla slough ssf llc slough subsequently acquired net book value health care properties lease property adjacent genentechs south san francisco site developed slough development included total eight buildings construction completed time genentech fully year ended december occupied property property lease extension options november genentech exercised january purchase option contained mla acquire eight buildings land december group recorded addition business combinations land buildings land improvements corresponding liabilities cash outflows group also additions reclassified finance lease accounting balances previously applied buildings november first closing payment disposals usd million made reduced shortterm liability see note final closing payment usd million due transfers july recorded longterm liability see note depreciation charge impairment charge leasing arrangements group lessee currency translation effects december finance leases december capitalised cost property plant equipment finance leases chf million chf million net book value assets chf million chf million carrying value leasing cost obligation chf million chf million reported part debt see note accumulated depreciation impairment net book value finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value minimum lease year ended december payments payments january business combinations within one year additions one five years disposals five years transfers total depreciation charge future finance charges impairment charge total future minimum lease payments undiscounted currency translation effects december operating leases group companies party number operating leases mainly property rentals motor vehicles arrangements impose significant restrictions group total operating lease rental expense chf million cost chf million accumulated depreciation impairment net book value operating leases future minimum lease payments noncancellable leases millions chf within one year classification impairment property plant equipment millions chf one five years five years total minimum payments cost sales marketing distribution research development general administration leasing arrangements group lessor total impairment charge finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements impairment charges property plant equipment mainly related global restructuring plans see note assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method reimbursements received insurance companies respect impairments property plant equipment none borrowing costs capitalised property plant equipment none roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group goodwill finance leases future minimum lease receipts noncancellable leases millions chf present value minimum gross investment lease lease receipts goodwill movements carrying value assets millions chf within one year one five years five years january total cost unearned finance income na na accumulated impairment unguaranteed residual value na na net book value net investment lease year ended december accumulated allowance uncollectible minimum lease payments chf million chf million january business combinations operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements impairment charge assets reported within property plant equipment lease income operating leases recognised lease term currency translation effects straightline basis december december machinery equipment original cost chf billion chf billion net book value cost chf billion chf billion leased third parties accumulated impairment net book value operating leases future minimum lease receipts noncancellable leases millions chf allocated following cashgenerating units roche pharmaceuticals within one year foundation medicine one five years chugai five years total pharmaceuticals division total minimum receipts diabetes care centralised point care solutions molecular diagnostics capital commitments tissue diagnostics sequencing group noncancellable capital commitments purchase construction property plant equipment totalling strategic goodwill held divisional level chf billion chf billion total diagnostics division impairment charge goodwill impairment charge chf million recorded pharmaceuticals division full writeoff goodwill anadys pharmaceuticals inc acquisition deemed disposed impairment charge impairments goodwill impairment testing pharmaceuticals division divisions operating segments cashgenerating units used testing goodwill part goodwill arising foundation medicine acquisition recorded monitored roche pharmaceuticals level relates strategic development roche pharmaceuticals therefore cashgenerating unit strategic goodwill roche pharmaceuticals recoverable amount used impairment testing higher value use fair value less costs disposal chugai foundation medicine fair value less costs disposal determined reference publicly quoted share prices chugai foundation medicine shares roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group intangible assets diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cashgenerating unit goodwill entire division recoverable amount used impairment intangible assets movements carrying value assets millions chf testing based value use product product intangibles marketing technology value use calculated using discounted expected cash flow approach posttax discount rate applied projected intangibles available intangibles intangibles riskadjusted posttax cash flows terminal value discount rate groups weighted average cost capital cash use use use use total generating units integrated operations across large parts group derived capital asset pricing model using data january capital markets including government twentyyear bonds assessing value use cash flow projections based cost recent business plans approved management business plans include managements latest estimates sales volume accumulated amortisation impairment pricing well production operating costs assume significant changes organisation key assumptions net book value used calculations period cash flow projections included business plans terminal value growth rate discount rate year ended december january key assumptions used value use calculations business combinations additions divestment subsidiary period terminal period terminal transfers cash flow value discount rate cash flow value discount rate projections growth rate tax projections growth rate tax amortisation charge pharmaceuticals division impairment charge roche pharmaceuticals years na years na currency translation effects diagnostics division december sequencing years years diagnostics businesses years years cost accumulated amortisation impairment cashgenerating units terminal value growth respective rate exceed longterm projected growth rate net book value relevant market ten years period cash flow projections reflects longterm nature sequencing business allocated operating segment roche pharmaceuticals sensitivity analysis chugai diagnostics management performed sensitivity analyses roche pharmaceuticals diagnostics division increased discount total group rate combined decreasing forecast cash flows chugai foundation medicine decreased publicly quoted share prices results sensitivity analyses demonstrated changes key assumptions year ended december would cause carrying value goodwill exceed recoverable amount december january additions disposal transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group significant intangible assets december millions chf intangible asset impairment remaining operating segment net book value amortisation period impairment charges arise changes estimates future cash flows expected result use asset product intangibles use eventual disposal factors presence absence competition technical obsolescence lower anticipated sales intermune acquisition roche pharmaceuticals years products capitalised rights could result shortened useful lives impairment foundation medicine acquisition roche pharmaceuticals years ariosa acquisition diagnostics years kapa acquisition diagnostics years impairment charges iquum acquisition diagnostics years pharmaceuticals division impairment charges totalling chf million recorded related product intangibles available use decision stop development one compound acquired part seragon acquisition following clinical data assessment trophos acquisition roche pharmaceuticals na chf million asset concerned yet amortised fully written biontech licence transaction roche pharmaceuticals na delay development compound acquired part trophos acquisition following regulatory feedback chf million geneweave acquisition diagnostics na asset concerned yet amortised written estimated recoverable value chf million cmi acquisition diagnostics na portfolio reassessment one compound chf million asset concerned yet amortised fully genia acquisition diagnostics na written clinical data assessment two development projects two different alliance partners chf million assets concerned technology intangibles use yet amortised fully written dutalys acquisition roche pharmaceuticals years decision stop development three compounds chf million assets concerned yet amortised fully written diagnostics division impairment charges totalling chf million recorded related classification intangible asset amortisation impairment expenses millions chf sequencing product intangibles use chf million result decision stop product development commercialisation license agreement alliance partner asset concerned amortised fully written amortisation impairment tissue diagnostics product intangibles use chf million result strategic portfolio reassessment asset concerned cost sales amortised fully written pharmaceuticals diagnostics marketing distribution impairment charges pharmaceuticals diagnostics pharmaceuticals division impairment charges totalling chf million recorded related research development decisions stop development four compounds different alliance partners chf million assets concerned pharmaceuticals yet amortised fully written diagnostics decision stop one collaboration project alliance partner chf million asset concerned amortised total fully written potential commitments alliance collaborations purchase agreements within next three years internally generated intangible assets group party inlicensing similar arrangements alliance partners intangible asset purchase agreements group currently internally generated intangible assets development criteria recognition asset third parties arrangements purchase agreements may require group make certain milestone similar payments met dependent upon achievement agreed objectives performance targets defined collaboration purchase agreements groups current estimate future thirdparty commitments payments within next three years set table intangible assets indefinite useful lives figures undiscounted riskadjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures group currently intangible assets indefinite useful lives include potential commitments within group may arise roche chugai businesses potential future thirdparty collaboration purchase payments december millions chf intangible assets available use pharmaceuticals diagnostics group mostly represent inprocess research development assets acquired either inlicensing arrangements business within one year combinations separate purchases december approximately projects pharmaceuticals one two years division known decision points within next twelve months certain circumstances could lead impairment due two three years inherent uncertainties research development processes intangible assets available use particularly risk total impairment project expected result commercialised product roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group inventories marketable securities inventories millions chf marketable securities millions chf raw materials supplies availableforsale financial assets work process equity securities intermediates debt securities finished goods money market instruments time accounts three months provision slowmoving obsolete inventory investments total inventories total marketable securities inventories expensed cost sales totalled chf billion chf billion inventory writedowns year marketable securities held fund management purposes primarily denominated swiss francs us dollars euros resulted expense chf million chf million money market instruments contracted mature within one year december debt securities contracted maturity millions chf accounts receivable within one year one five years five years accounts receivable millions chf total debt securities trade receivables notes receivable receivables cash cash equivalents allowances doubtful accounts chargebacks allowances withheld upon settlement total accounts receivable cash cash equivalents millions chf allowances doubtful accounts movements recognised liability millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents january additional allowances created unused amounts reversed utilised year currency translation effects december bad debt expenses recorded marketing distribution costs totalled chf million expense chf million roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group noncurrent assets accounts payable noncurrent assets millions chf accounts payable millions chf availableforsale investments held fair value trade payables availableforsale investments held cost taxes payable loans receivable dividends payable longterm trade receivables payables restricted cash total accounts payable receivables total financial noncurrent assets longterm employee benefits assets noncurrent liabilities total nonfinancial noncurrent assets associates noncurrent liabilities millions chf total noncurrent assets availableforsale investments mainly equity investments private biotechnology companies kept part groups deferred income strategic alliance efforts unquoted equity investments classified availableforsale measured cost fair value longterm liabilities measured reliably total noncurrent liabilities longterm liabilities mainly related accrued employee benefits longterm genentech property purchase option exercise obligation see note current assets current liabilities current assets millions chf accrued interest income current liabilities millions chf derivative financial instruments restricted cash receivables deferred income total financial current assets accrued payroll related items interest payable prepaid expenses derivative financial instruments taxes recoverable accrued chargebacks allowances separately payable assets accrued royalties commissions total nonfinancial current assets accrued liabilities total current liabilities total current assets december accrued liabilities included chf million shortterm genentech property purchase option exercise receivables mainly related royalty licensing income receivables obligation paid november see note roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group provisions contingent liabilities environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts provisions movements recognised liabilities millions chf timings outflows difficult predict significant provisions discounted time value money material significant provisions relate us site nutley new jersey divested september legal environmental restructuring employee provisions provisions provisions provisions provisions total estimated remediation costs landfill site near grenzach germany used manufacturing operations closed year ended december years ago estimated remediation costs manufacturing site clarecastle ireland part divestment nutley january site expected costs environmental remediation reassessed accordingly environmental provisions increased additional provisions created chf million unused amounts reversed utilised discount unwind restructuring provisions business combinations acquired companies arise planned programmes materially change scope business undertaken group manner deferred consideration business conducted provisions include costs necessarily entailed restructuring associated contingent consideration recurring activities group timings cash outflows reasonably certain provisions discounted movements time value money material matters currency translation effects december pharmaceuticals division significant provisions relate strategic realignment manufacturing network including exiting four manufacturing sites see note research development strategic alignment outsourcing functions current shared service centres external providers noncurrent december employee provisions year ended december january mostly relate certain employee benefit obligations sabbatical leave longservice benefits timings cash additional provisions created outflows reasonably estimated based past experience unused amounts reversed utilised discount unwind provisions business combinations acquired companies timing cash outflows nature uncertain provisions relate items shown table deferred consideration contingent consideration provisions millions chf movements currency translation effects december contingent consideration sales returns current items noncurrent total provisions december expected outflow resources within one year contingent liabilities one two years two three years operations earnings group continue time time varying degrees affected political legislative fiscal three years regulatory developments including relating environmental protection countries operates industries december group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise legal provisions companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments legal provisions consist number separate legal matters including claims arising trade various group companies payments given note nature amounts timings outflows difficult predict legal expenses totalled chf million chf million reflect recent developments various legal matters details major legal cases outstanding disclosed roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group pharmaceuticals legal cases tarceva subpoena november genentech received subpoena us department justice doj requesting documents information related promotion tarceva prescription product initially approved treatment locally december provisions legal cases pharmaceuticals division chf million chf million provisions advanced metastatic nonsmall cell lung cancer failure least one prior chemotherapy regimen later approved recorded cases settled mainly relating matters listed additional indications genentech cooperating associated investigation may government representatives presented first time governments civil liability theory specifically genentech allegedly participated offlabel promotion accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal tarceva causing submission false claims reimbursement civil false claims act august government actions us elsewhere relating acne medication accutane litigation alleges accutane caused certain serious closed criminal investigation genentech june genentech executed settlement agreements us department conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders hlr justice states resolving civil investigation matter federal government states announced following reevaluation portfolio medicines available generic manufacturers rapidly concluded declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product us rituxan arbitration october genentech biogen idec inc filed complaint california sanofiaventis deutschland gmbh sanofiaventis us llc sanofiaventis us inc sanofi seeking declaratory judgment certain genentech products actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation mdl including rituxan infringe sanofis us patent nos patents invalid sanofi us district court middle district florida tampa division august mdl closed pendency alleged rituxan another genentech product infringe certain claims patents march district court mdl district court granted summary judgment favour hlr federal ibd cases proceeded ruled matter law genentech biogen idec infringe asserted patent claims may sanofi appealed affirmed us court appeals eleventh circuit actions pending state court new jersey alleging ibd courts noninfringement ruling appellate court affirmed district courts judgment patent infringement consolidated pretrial proceedings superior court new jersey law division atlantic county addition october sanofi affiliate hoechst gmbh hoechst filed icc international court arbitration paris since january approximately cases dismissed us december approximately request arbitration genentech relating terminated patentlicence agreement one hoechsts predecessors dismissed cases appeal hlr defending approximately actions involving approximately plaintiffs brought genentech pertained abovementioned patents related patents outside us hoechst sought payment patent various federal state courts throughout us personal injuries allegedly resulting use accutane licence royalties sales certain genentech products including rituxan damages breach contract relief various arbitral awards september february arbitrator found genentech liable hoechst patentlicence royalties february superior court new jersey law division atlantic county held eightday evidentiary hearing whether rituxan awarded royalties interest hoechst sought february group recorded back royalty expense plaintiffs experts testify accutane causes crohns disease february superior court barred plaintiffs experts chf million net assumed reimbursement portion groups obligation copromotion partner us methods meet requirements scientific reliability may superior court entered order dismissing prejudice agreedupon list crohns disease cases subject superior courts february hoechst initiated proceedings us france germany seeking enforce arbitral awards october genentech paid order may superior court entered order granting summary judgment dismissing cases filed new jersey awarded royalties interest hoechst protest genentech seeking annulment arbitral awards proceedings residents basis drug label adequate matter law since july superior court granted hlrs initiated court appeal paris hearing proceedings june september paris court motion summary judgment adequacy label post ingestion cases jurisdictions superior court appeal stayed annulment proceedings seek guidance eu court justice specific legal question applied new jersey law jurisdictions granted hlrs motion dismissing approximately cases alternative raised genentech relating arbitral awards noncompliance eu competition laws november hoechst filed notices superior court applied home state law granted summary judgment jurisdictions denied jurisdictions would appeal french supreme court seeking review paris court appeals decision seek guidance eu court resulted cases dismissed january october superior court entered orders granting summary judgment justice november french supreme court denied hoechsts challenge decision paris court appeals dismissing cases failure prove accutane proximately caused ulcerative colitis plaintiffs appealed refer specific legal question eu court justice july eu court justice issued opinion case finding decisions licensee may freely terminate licence licence anticompetitive case proceeding paris court appeal hearing expected first half outcome matter determined time december juries new jersey superior court ruled favour plaintiff eight cases assessing compensatory damages totalling usd million eight cases ruled favour plaintiff superior court one case average wholesale prices litigation hlr roche laboratories inc rli along approximately brand generic settled seven cases verdicts reversed favour hlr usd million one case usd million pharmaceutical companies named defendants several legal actions us relating pricing pharmaceutical appeal new jersey appellate division drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp andor wholesale acquisition costs wac drugs superior court new jersey law division atlantic county scheduled february evidentiary hearing whether prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states plaintiffs experts testify accutane causes ulcerative colitis cases survive hearing additional trials may scheduled respective attorney general seeking repayment amounts claim overreimbursed time period individual trial results depend variety factors including many unique particular case therefore trial associated cases december hlr rli defending one awp action filed state results date may predictive future trial results group continues defend vigorously remaining personal injury cases new jersey hlr rli vigorously defending trial date set outcome matter claims determined time avastinlucentis investigations february italian antitrust authority agcm announced investigation determine addition matters listed currently provisions recorded potential future obligations whether roche genentech novartis entered agreement restrict competition italian market drugs confirmed occurrence nonoccurrence uncertain future events obligation measured reference particular avastin marketed roche lucentis marketed novartis avastin lucentis two different sufficient reliability drugs developed approved different therapeutic purposes contain different active pharmaceutical ingredients march agcm issued verdict alleges roche novartis colluded artificially differentiate avastin lucentis boniva litigation hlr genentech various roche affiliates collectively roche named defendants numerous order foster sales lucentis italy agcm fined roche eur million novartis eur million roche appealed legal actions us one dismissed case canada relating postmenopausal osteoporosis medication boniva agcm verdict tribunale amministrativo regionale del lazio tar december tar upheld decision litigations plaintiffs allege boniva caused either osteonecrosis jaw atypical femoral fractures december agcm roche strongly disagrees verdict tar appealed may italian ministry health notified roche defending approximately actions involving approximately plaintiffs brought federal state courts throughout roche spa intention seek damages related matter july roche paid eur million fine protest us personal injuries allegedly resulting use boniva cases early discovery stages litigation avoid additional penalty fees recorded expense within general administration fine related interest reimbursed individual trial results depend variety factors including many unique particular case roche vigorously defending roche wins case outcome matters determined time matters outcome matters determined time roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group ema investigation october european medicines agency ema announced would start infringement bonds notes procedure investigate allegations regarding alleged breach medicines safety reporting obligations relation centrally authorised medicines november ema announced results pharmacovigilance risk assessment committee recognised liabilities effective interest rates bonds notes millions chf assessment roches medicines ema found impact regarding benefitrisk balance roches medicines effective interest rate confirmed benefitrisk profiles based available safety information ema health authorities confirmed underlying including medicines remain authorised without changes treatment advice patients healthcare professionals corrective instrument hedging preventative actions resulting inspections implemented reinspection authorities november led us dollar notes fixed rate certain findings roche addressing april ema issued report european commission notes due september principal usd billion summarises emas findings relation investigation july european commission issued notification isin usbc ema returning case file ema new period inquiry july ema announced concluded notes due march principal usd billion second inquiry sent july final updated report european commission european commission isin usuam usas decide whether matter pursued financial penalties imposed decision european commission notes due september principal usd billion isin usba matter still pending outcome matter determined time notes due september principal usd billion isin usbb na notes due january principal usd billion isin usbm notes due september principal usd billion isin usbe na debt notes due november principal usd billion isin usbj na notes due may principal usd billion isin usbk na notes due january principal usd billion isin usbl na debt movements carrying value recognised liabilities millions chf notes due march principal usd billion outstanding usd billion isin usuan usau notes due november principal usd billion isin usbh na january proceeds issue bonds notes us dollar notes floating rate redemption repurchase bonds notes notes due september principal usd billion isin usbd na increase decrease commercial paper notes due september principal usd billion isin usaz na increase decrease debt net gains losses redemption repurchase bonds notes euro medium term note programme fixed rate loss major debt restructuring notes due march principal gbp billion isin xs amortisation debt discount notes due march principal eur billion isin xs business combinations notes due june principal eur billion isin xs na net foreign currency transaction gains losses notes due march principal usd billion isin xs currency translation effects notes due march principal eur billion december outstanding eur billion isin xs notes due february principal eur billion isin xs na bonds notes notes due august principal gbp billion commercial paper outstanding gbp billion isin xs na amounts due banks financial institutions notes due february principal eur billion isin xs na finance lease obligations borrowings swiss franc bonds fixed rate total debt bonds due march principal chf billion isin ch na bonds due september principal chf billion isin ch longterm debt bonds due september principal chf billion shortterm debt isin ch total debt genentech senior notes pledges groups assets connection debt senior notes due july principal usd billion isin usag na senior notes due july principal usd billion outstanding usd billion isin usac na total bonds notes roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group bonds notes maturity millions chf redemption repurchase bonds notes redemption us dollar denominated notes december group resolved exercise option call early within one year partial redemption fixed rate notes due march march group redeemed outstanding principal one two years usd million amount equal sum present values remaining scheduled payments notes discounted two three years redemption date us treasury rate plus together accrued unpaid interest principal cash outflow three four years chf million plus accrued interest december group revised carrying value notes take account four five years changes amounts timings estimated cash flows resulted increase carrying value usd million five years chf million recorded within financing costs see note loss redemption additional total bonds notes chf million loss recorded redemption effective interest rate notes june group resolved exercise option call early partial redemption fixed rate notes due march august group redeemed outstanding principal usd million amount equal sum present values unamortised discount included carrying value bonds notes millions chf remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow chf million plus accrued interest loss redemption chf million effective interest rate notes us dollar notes euro notes december group completed tender offer repurchase usd million fixed rate notes due march swiss franc bonds cash outflow chf million plus accrued interest loss repurchase chf million effective interest pound sterling notes rate notes total unamortised discount redemption euro notes due date march group redeemed fixed rate notes principal eur billion cash outflow chf million plus accrued interest effective interest rate notes issuance bonds notes redemption repurchase bonds notes february group issued eur million fixed rate notes coupon euro medium term note programme notes mature february listed luxembourg stock exchange group received partial redemption us dollar notes december group resolved exercise option call early partial chf million aggregate net proceeds issuance sale fixed notes redemption fixed rate notes due march march group redeemed outstanding principal usd million amount equal sum present values remaining scheduled payments notes discounted march group completed offering usd billion fixed rate notes coupon notes mature redemption date us treasury rate plus together accrued unpaid interest principal cash outflow may group received chf million aggregate net proceeds issuance sale fixed notes chf million plus accrued interest additional chf million loss recorded redemption effective interest rate notes october group completed offering usd million usd million fixed rate notes coupon respectively notes mature january january respectively group received september group completed tender offer repurchase usd million fixed rate notes due march chf million aggregate net proceeds issuance sale fixed notes cash outflow chf million plus accrued interest loss repurchase chf million effective interest rate notes issuance bonds notes september group completed tender offer repurchase usd million fixed rate notes due march cash outflow chf million plus accrued interest loss repurchase chf million effective interest february group issued eur billion fixed rate notes coupon euro medium term note rate notes programme notes mature february listed luxembourg stock exchange group received chf million aggregate net proceeds issuance sale fixed notes redemption pound sterling notes due date march group redeemed fixed rate notes principal gbp million cash outflow chf million plus accrued interest effective interest rate notes march group issued usd million fixed rate notes coupon euro medium term note programme notes mature march listed luxembourg stock exchange group received redemption genentech senior notes due date july group redeemed fixed rate senior notes chf million aggregate net proceeds issuance sale fixed notes principal usd billion cash outflow chf million plus accrued interest effective interest rate notes november group completed offering usd billion fixed rate notes coupon notes mature november group received chf million aggregate net proceeds issuance sale fixed notes partial repurchase genentech senior notes september group repurchased usd million fixed rate senior notes due july cash outflow chf million plus accrued interest loss repurchase major debt restructuring september group decided major debt restructuring group raised net proceeds chf million effective interest rate notes chf million debt offering described newly issued debt senior unsecured guaranteed roche holding ltd group repurchased usd million fixed rate notes due march usd million fixed rate partial repurchase euro notes november group repurchased eur million fixed rate notes due notes due march usd million fixed rate genentech senior notes due july eur million fixed march cash outflow chf million plus accrued interest loss repurchase chf million rate notes due march major debt restructuring resulted loss repurchase chf million effective interest rate notes roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group equity attributable roche shareholders cash flows issuance redemption repurchase bonds notes cash inflows issuance bonds notes millions chf changes equity attributable roche shareholders millions chf reserves euro medium term note programme euro notes retained euro medium term note programme us dollar notes share capital earnings fair value hedging translation total us dollar notes year ended december total cash inflows issuance bonds notes january net income recognised income statement cash outflows redemption repurchase bonds notes millions chf availableforsale investments fair value gains losses taken equity transferred income statement euro medium term note programme pound sterling notes income taxes euro medium term note programme euro notes noncontrolling interests us dollar notes cash flow hedges total cash outflows redemption repurchase bonds notes gains losses taken equity transferred income statement income taxes noncontrolling interests commercial paper currency translation foreign operations exchange differences roche holdings inc commercial paper program roche holdings inc established commercial paper program noncontrolling interests issue usd billion unsecured commercial paper notes guaranteed roche holding ltd total committed credit lines defined benefit plans available backstop supporting commercial paper program usd billion december maturity remeasurement gains losses notes program exceed days date issuance december unsecured commercial paper notes limit asset recognition principal amount usd billion average interest rate outstanding income taxes noncontrolling interests movements commercial paper obligations millions chf comprehensive income net tax total comprehensive income january net cash proceeds payments dividends currency translation effects equity compensation plans net transactions equity december changes noncontrolling interests december entire amount transferred income statement reported financial income expense amounts due banks financial institutions amounts denominated various currencies notably chinese renminbi average interest rate december amounts outstanding chf million chf million due within one year roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group changes equity attributable roche shareholders millions chf share capital reserves december authorised issued share capital roche holding ltd groups parent company consisted retained share capital earnings fair value hedging translation total million shares nominal value chf preceding year shares bearer shares group year ended december maintain register shareholders based information supplied group shareholder group pooled voting rights owns january issued shares march shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition shareholder group pooled voting rights net income recognised income statement holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool availableforsale investments holds shares representing voting rights independently pool described note based fair value gains losses taken equity information supplied group novartis holding ag basel owns participation issued shares transferred income statement income taxes noncontrolling interests cash flow hedges nonvoting equity securities genussscheine gains losses taken equity transferred income statement december nonvoting equity securities authorised issue preceding year income taxes swiss company law nonvoting equity securities nominal value part share capital noncontrolling interests issued contribution would shown asset balance sheet roche holding ltd nonvoting equity currency translation foreign operations security confers rights shares participate net profit remaining proceeds liquidation exchange differences following repayment nominal value shares participation certificates accordance law articles noncontrolling interests incorporation roche holding ltd company entitled times exchange nonvoting equity securities defined benefit plans shares participation certificates remeasurement gains losses limit asset recognition income taxes dividends noncontrolling interests comprehensive income net tax march shareholders approved distribution dividend chf per share nonvoting equity security chf respect business year distribution holders outstanding shares nonvoting equity securities total comprehensive income totalled chf million chf million recorded retained earnings board directors proposed dividends business year chf per share nonvoting equity security approved would result dividends total distribution shareholders chf million subject approval annual general meeting march equity compensation plans net transactions equity changes noncontrolling interests december equity instruments entire amount transferred income statement reported financial income expense holdings equity instruments equivalent number nonvoting equity securities millions millions genentech transaction shares nonvoting equity securities group completed purchase noncontrolling interests genentech effective march based international total accounting standard separate financial statements ias consistent international financial reporting standard consolidated financial statements ifrs adopted group transaction accounted full equity instruments recorded within equity original purchase cost december fair value shares equity transaction consequence carrying amount consolidated equity group time reduced chf million nonvoting equity securities chf billion equity instruments held groups potential conversion chf billion chf billion allocated eliminate book value genentech noncontrolling interests obligations may arise groups equity compensation plans see note accounting effect significantly impacted groups net equity effect groups business dividend policy reserves fair value reserve fair value reserve represents cumulative net change fair value availableforsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group subsidiaries licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai also right first refusal development marketing japan development compounds advanced roche chugai rest world umbrella rights agreement excluding japan south korea signed may revised amended effective october roche group chugai completed alliance create leading researchdriven japanese restated rest world umbrella rights agreement excluding japan south korea taiwan signed august pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche agreement roche right first refusal development marketing chugais development compounds merged company known chugai markets outside japan excluding south korea taiwan consolidated subsidiary chugai fully consolidated subsidiary group based groups interest chugai agreements roche chugai signed series separate agreements certain specific products depending december roche relationship chugai founded basic alliance licensing specific circumstances terms agreement may result payments arms length basis roche research collaboration agreements chugai following matters upfront payments right first refusal license product exercised common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai milestone payments dependent upon achievement agreed performance targets prepares financial statements accordance international financial reporting standards ifrs filed quarterly basis royalties future product sales tokyo stock exchange due certain consolidation entries minor differences chugais standalone ifrs results results chugai consolidated roche group accordance ifrs specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis chugai summarised financial information millions chf research collaboration agreements roche chugai entered research collaboration agreements areas small molecule synthetic drug research biotechnologybased drug discovery income statement sales royalties operating income foundation medicine total revenues operating profit april group acquired controlling interest foundation medicine inc fmi entered investor rights agreement research development collaboration agreement several commercial collaboration agreements balance sheet noncurrent assets fmi fully consolidated subsidiary group based groups interest fmi december current assets roche relationship fmi founded agreements common stock fmi publicly traded noncurrent liabilities listed nasdaq stock code fmi fmi prepares financial statements accordance us gaap filed current liabilities quarterly basis sec due certain consolidation entries differences fmis standalone us gaap results total net assets results fmi consolidated roche group accordance ifrs cash flows dividends dividends distributed third parties holding fmi shares cash flows operating activities cash flows investing activities cash flows financing activities dividends dividends distributed third parties holding chugai shares totalled chf million chf million recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group noncontrolling interests pensions postemployment benefits changes equity attributable noncontrolling interests millions chf groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations january fiscal requirements market practice countries employees employed postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial net income recognised income statement institution legal constructive obligation pay contributions plans classified defined chugai benefit plans noncontrolling interests total net income recognised income statement defined contribution plans availableforsale investments cash flow hedges defined contribution plans funded payments employees group funds administered third parties currency translation foreign operations groups expenses plans chf million chf million assets liabilities recognised groups remeasurements defined benefit plans balance sheet respect plans apart regular prepayments accruals contributions withheld employees comprehensive income net tax wages salaries groups contributions groups major defined contribution plan us roche k savings plan total comprehensive income defined benefit plans business combinations dividends noncontrolling shareholders plans usually established trusts independent group funded payments group companies employees chugai cases notably major defined benefit plans germany plans unfunded group pays pensions retired noncontrolling interests employees directly financial resources plans usually governed senior governing body board trustees equity compensation plans net transactions equity typically composed employee employer representatives funding plans determined local regulations changes noncontrolling interests using independent actuarial valuations separate independent actuarial valuations prepared accordance requirements equity contribution noncontrolling interests ias use groups financial statements groups major pension plans located switzerland us germany december total account groups defined benefit obligation chugai pension plans switzerland current pension arrangements employees switzerland made plans governed noncontrolling interests swiss federal occupational old age survivors disability pension act bvg groups pension plans administered total noncontrolling interests separate legal foundations funded regular employee company contributions final benefit contributionbased certain minimum guarantees due minimum guarantees swiss plans treated defined benefit plans purposes ifrs financial statements although many characteristics defined contribution plans underfunding may remedied various measures increasing employee company contributions lowering interest rate retirement account balances reducing prospective benefits suspension early withdrawal facility employee benefits operating income chf million recorded past service costs changes groups pension plans switzerland announced june represents impact adjustment pension liability plan changes amount chf million recorded pharmaceuticals division chf million diagnostics division employee remuneration millions chf chf million corporate past service income recorded within general administration part adjustments pension plans switzerland group made payments chf million pension funds wages salaries pension plans us groups major defined benefit plans us closed new members since new social security costs employees us join defined contribution plan largest remaining defined benefit plans funded pension plans defined contribution plans including separate plans originating nutley palo alto indianapolis sites together smaller unfunded supplementary operating expenses defined benefit plans retirement plans benefits based highest average annual rate earnings specified period length equity compensation plans employment plans noncontributory employees group making periodic payments plans termination costs underfunding would normally remedied additional company contributions payments made group employee benefits usd million usd million increased contribution group benefitted lower insurance fee pension employee remuneration included operating results benefit guarantee corporation us government agency overseeing occupational pension schemes us net interest cost defined benefit plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group pension plans germany groups major pension arrangements germany governed occupational pensions act defined benefit plans funding status millions chf betravg plans unfunded group pays pensions retired employees directly financial resources plans noncontributory employees benefits based final salary length employment plans post post closed new members since replaced new plan funded regular employee company pension employment pension employment contributions administered contractual trust agreement final benefit contributionbased minimum guarantee plans benefit plans total plans benefit plans total due minimum guarantee plan treated defined benefit plan purposes ifrs financial statements funded plans although many characteristics defined contribution plan fair value plan assets defined benefit obligation pension plans rest world represent approximately groups defined benefit obligation funding consist number smaller plans various countries largest pension plans chugai independently unfunded plans managed chugai main pension plan united kingdom chugai plans fully described chugais ifrs defined benefit obligation financial statements uk pension plan funded regular employee company contributions benefits based final salary total funding status length employment plan closed new members since replaced defined contribution limit asset recognition plan group made payments eur million pension funds ireland relation restructuring reimbursement rights manufacturing site clarecastle net recognised asset liability postemployment benefit opeb plans represent approximately groups defined benefit obligation reported balance sheet consist postretirement healthcare life insurance schemes mainly us plans mainly unfunded defined benefit plan assets contributory employees group reimbursing retired employees directly financial resources groups defined benefit plan liabilities major opeb plans us closed new members since part costs plans reimbursable medicare prescription drug improvement modernization act statutory funding requirement plans group funding plans extent tax efficient payments made group plans none december ifrs funding status including reimbursement rights funded plan assets opeb plans us responsibility investment strategies funded plans senior governance body board trustees asset defined benefit plans income statement millions chf liability studies performed regularly major pension plans studies examine obligations postretirement benefit plans evaluate various investment strategies respect key financial measures expected returns expected risks expected contributions expected funded status plan interdependent way goal assetliability study select post post appropriate asset allocation funds held within plan investment strategy developed optimise expected returns pension employment total pension employment total plans benefit plans expense plans benefit plans expense manage risks contain fluctuations statutory funded status assetliability studies include strategies match cash flows current service cost assets plan obligations group currently use annuities longevity swaps manage longevity risk past service income cost settlement gain loss plan assets managed using internal external asset managers actual performance continually monitored pension total operating expenses fund governance bodies well closely monitored corporate level financial statements difference interest income actual return plan assets remeasurement recorded directly comprehensive income net interest cost defined benefit plans actual return plan assets gain chf million loss chf million total expense recognised income statement recognition pension assets limited present value economic benefits available refunds plans reductions future contributions plans funding status defined benefit plans fair value plan assets reimbursement rights millions chf funding groups various defined benefit plans responsibility senior governing body board trustees post post sponsoring employer managed based local statutory valuations follow legislation requirements pension employment pension employment respective jurisdiction plan established qualified independent actuaries carry statutory actuarial valuations plans benefit plans total plans benefit plans total regular basis actuarial assumptions determining funding status statutory basis regularly assessed local senior january governing body funding status closely monitored corporate level unfunded plans mainly groups german interest income plan assets affiliates fully reserved pension obligations invested local affiliates operations remeasurements plan assets currency translation effects ifrs funded status funded defined benefit plans improved employer contributions employee contributions reimbursement rights linked postemployment medical plans us represent expected reimbursement benefits paid funded plans medical expenditure provided medicare prescription drug improvement modernization act benefits paid settlements administration costs december roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group defined benefit plans composition plan assets millions chf defined benefit plans defined benefit obligation millions chf post post equity securities pension employment pension employment debt securities plans benefit plans total plans benefit plans total property january cash money market instruments current service cost investments interest cost december remeasurements demographic assumptions assets invested variety different classes order maintain balance risk return follows financial assumptions equity debt securities mainly quoted market prices level fair value hierarchy experience adjustments property mainly private commercial property funds mainly observable inputs level fair value currency translation effects hierarchy movements cash money market instruments mainly invested financial institutions credit rating lower employee contributions investments mainly consist alternatives mortgages commodities insurance contracts used risk benefits paid funded plans management purposes mainly observable inputs level fair value hierarchy unobservable inputs level fair value benefits paid unfunded plans hierarchy benefits paid settlements past service income cost included within fair value plan assets groups shares nonvoting securities fair value chf million settlement gain loss chf million debt instruments issued group fair value chf million chf million december composition plan defined benefit obligation active members deferred vested members defined benefit obligation calculated using projected unit credit method reflects service rendered employees retired members dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value december benefits projected rates remuneration growth mortality rates present value defined benefit obligation determined discounting estimated future cash outflows using interest rates highquality corporate bonds government bonds countries plans geography deep market corporate bonds corporate government bonds denominated currency switzerland benefits paid maturity terms approximating terms related pension obligation united states germany groups final salarybased defined benefit pension plans us germany united kingdom closed new rest world participants active employees members pension plans time closed new participants continue december accrue benefits final salarybased defined benefit pension plans new employees us uk join groups defined contribution plans new employees germany join contributionbased plan minimum guarantee result duration years proportion defined benefit obligation relates closed plans expected decrease future defined benefit pension plans switzerland final benefit contributionbased minimum guarantee remain open new employees actuarial assumptions actuarial assumptions used financial statements based requirements set ias employee benefits unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management based advice actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates salary benefit levels inflation rates costs medical benefits actuarial assumptions vary based upon local economic social conditions actuarial assumptions used various statutory valuations may differ based local legal regulatory requirements roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality sensitivity analysis considers change one assumption time leaving assumptions unchanged approach tables take account historic patterns expected changes increases longevity rates employee shows isolated effect changing one individual assumption take account assumptions related turnover disability early retirement based historical behaviour average life expectancy assumed individual method used carry sensitivity analysis prior year age follows defined benefit plans average life expectancy age major schemes years cash flows male female country mortality table group incurred cash flows defined benefit plans shown table switzerland bvg projected cmi model united states rp projected mp defined benefit plans cash flows millions chf germany heubeck tables g bvg generational tables used employer contributions net reimbursements funded plans december mortality assumptions used pension plans switzerland based bvg applying benefits paid unfunded plans continuous mortality investigation cmi model group believes better reflects mortality improvement factors longterm rate total cash inflow outflow used longevity improvements defined benefit obligation measured mortality assumption approximately chf million lower compared respective amount measured using bvg generational tables based recent actuarial valuations group expects employer contributions funded plans approximately chf million includes estimated chf million additional contributions mostly related us defined benefit plans financial assumptions based market expectations period obligations settled benefits paid unfunded plans estimated approximately chf million mostly relate german defined assumptions used actuarial valuations shown benefit plans defined benefit plans financial actuarial assumptions weighted weighted equity compensation plans average range average range discount rates expected rates salary increases expected rates pension increases group operates several equity compensation plans including separate plans chugai foundation medicine ifrs share expected inflation rates based payment requires fair value equity compensation plan awards granted employees estimated grant date immediate medical cost trend rate recorded expense vesting period ultimate medical cost trend rate expenses equity compensation plans millions chf discount rates determined reference interest rates highquality corporate bonds government bonds countries deep market corporate bonds expected rates salary increases based expected inflation rates adjustment reflect groups latest expectation longterm real salary increases expected rates pension increases cost sales generally linked expected inflation rate funding status plan expected inflation rates derived looking level marketing distribution inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well research development economic variables circumstances medical cost trend rates take account benefits set plan terms general administration expected future changes medical costs since groups major postemployment medical plans us employees rates total operating expenses driven developments us equity compensation plans sensitivity analysis measurement net defined benefit obligation particularly sensitive changes discount rate roche stocksettled stock appreciation rights inflation rate expected mortality medical cost trend rate assumptions following table summarises impact change roche restricted stock unit plan assumptions present value defined benefit obligation roche performance share plan roche connect defined benefit plans sensitivity defined benefit obligation actuarial assumptions millions chf roche option plan bonus stock awards chugai foundation medicine plans year increase life expectancy total operating expenses discount rates increase decrease equitysettled expected inflation rates cashsettled increase decrease immediate medical cost trend rate increase decrease roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group cash inflow outflow equity compensation plans millions chf roche rsus movement number awards outstanding number awards number awards roche option plan exercises thousands thousands chugai foundation medicine plans exercises outstanding january roche connect costs granted transactions equity forfeited total cash inflow outflow equitysettled equity compensation plans transferred participants net transactions equity outstanding december vested transferable net cash outflow transactions equity mainly arises sales purchases equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note roche performance share plan group offers future share nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers nontradable equitysettled awards equity compensation plans programme currently operates annual threeyear cycles roche performance share plan psp includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable roche stocksettled stock appreciation rights group issues stocksettled stock appreciation rights ssars certain number shares nonvoting equity securities individual award granted amount shares nonvoting directors management employees selected discretion group ssars give employees right receive non equity securities allocated depend upon individuals salary level achievement performance targets linked groups voting equity securities reflecting value appreciation market price nonvoting equity securities total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period grant date exercise date roche ssar plan million ssars available issuance tenyear period date grant discretion board directors award result zero two shares non rights nontradable equitysettled awards sevenyear duration vest phased basis three years voting equity securities value adjustment depending upon achievement performance targets roche ssars movement number rights outstanding roche performance share plan terms outstanding awards december weighted average weighted average number awards outstanding thousands number rights exercise price number rights exercise price thousands chf thousands chf vesting period years years years outstanding january allocated recipients feb feb feb granted fair value per unit grant chf forfeited total fair value grant chf millions exercised expired outstanding december roche connect programme enables employees worldwide except us certain countries make exercisable regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million cost plan chf million chf million roche ssars terms rights outstanding december roche option plan programme used countries ssars used awards plan give employees right rights outstanding rights exercisable purchase nonvoting equity securities exercise price specified grant date options nontradable equity number weighted average weighted average number weighted average settled awards sevenyear duration vest phased basis three years outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf roche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted total forfeited exercised expired roche restricted stock unit plan group issues restricted stock units rsus awards certain directors management outstanding december employees selected discretion group rsus nontradable represent right receive nonvoting equity exercisable securities vest threeyear period subject performance conditions currently performance conditions outstanding rsus december roche rsu plan million nonvoting equity securities available issuance tenyear period roche rsu plan also includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group earnings per share nonvoting equity security roche option plan terms options outstanding december options outstanding options exercisable weighted average weighted average weighted average basic earnings per share nonvoting equity security number outstanding years remaining exercise price number exercisable exercise price year grant thousands contractual life chf thousands chf net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number shares nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions total basic earnings per share nonvoting equity security chf weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april number awards fair diluted earnings per share nonvoting equity security value per award calculated grant date net income attributable roche shareholders chf millions fair value measurement increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions inputs used measurement fair values grant date equity compensation plans follows net income used calculate diluted earnings per share chf millions fair value measurement weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions roche stocksettled roche weighted average number shares nonvoting equity securities issue used stock appreciation roche restricted performance share roche option rights stock unit plan plan plan calculate diluted earnings per share millions progressively cliff vesting cliff vesting progressively vesting period years years years years diluted earnings per share nonvoting equity security chf contractual life years na na years number granted year thousands weighted average fair value chf model used binomial market pricea monte carlob binomial inputs option pricing model share price grant date chf exercise price chf expected volatility c na na expected dividend yield na na early exercise factor na na expected exit rate na na fair value roche rsus equivalent share price date grant b input parameters covariance matrix roche individual companies peer group based threeyear history riskfree rate minus valuation takes account defined rank performance structure determines payout plan c volatility determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group statement cash flows cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments cash flows operating activities also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses cash flows shortterm borrowings shown net movement consist large number transactions short calculated indirect method adjusting groups operating profit operating income expenses cash flows maturity example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities dividends paid millions chf cash generated operations millions chf dividends roche group shareholders dividends noncontrolling shareholders chugai net income dividends noncontrolling shareholders add back nonoperating income expense increase decrease dividends payable financing costs dividend withholding tax financial income expense total income taxes operating profit depreciation property plant equipment significant noncash transactions amortisation intangible assets impairment goodwill significant noncash transactions except contingent consideration arrangements arising business impairment intangible assets combinations see notes impairment reversal property plant equipment operating income expense defined benefit plans significant noncash transactions except contingent consideration arrangements arising business operating expense equitysettled equity compensation plans combinations see notes genentech property purchase option exercise see note net income expense provisions bad debt reversal expense inventory writedowns inventory fair value adjustment net gain loss disposal products adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group risk management nature geographic location counterparties accounts receivable overdue impaired shown table include balances us national wholesalers southern europe public customers described group risk management accounts receivable overdue nature geographical location counterparties millions chf risk management fundamental element groups business practice levels encompasses different types risks whole whole group level risk management integral part business planning controlling processes material risks monitored salers salers regularly discussed corporate executive committee audit committee board directors regions total public distributors private total public distributors private switzerland europe financial risk management north america latin america group exposed various financial risks arising underlying operations corporate finance activities groups japan financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well asia australia oceania creditworthiness solvency groups counterparties rest world total financial risk management within group governed policies reviewed boards directors roche chugai foundation medicine appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk ageing accounts receivable impaired shown table policies provide guidance risk limits type authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday ageing accounts receivable impaired millions chf risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai foundation medicine neither overdue impaired overdue month credit risk overdue months overdue months credit risk arises possibility counterparties transactions may default obligations causing financial losses overdue months group objective managing counterparty credit risk prevent losses liquid funds deposited invested overdue year counterparties maximum exposure credit risk resulting financial activities without considering netting agreements total accounts receivable without taking account collateral held credit enhancements equal carrying value groups financial assets cash marketable securities december group cash marketable securities chf billion accounts receivable december group trade receivables chf billion chf billion subject chf billion subject policy restricting exposures highquality counterparties setting defined limits policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation individual counterparties limits counterparty credit ratings reviewed regularly investments marketable securities account monitoring procedures objective trade receivables management maximise collection unpaid amounts entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity cash shortterm time deposits subject rules limit groups exposure december groups combined trade receivables balance three us national wholesale distributors amerisourcebergen individual financial institutions corp mckesson corp cardinal health inc equivalent chf billion representing groups consolidated trade receivables chf billion representing significant concentration counterparty credit risk due rating analysis cash fixed income marketable securities market values groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties group obtains credit insurance similar enhancements appropriate protect chf total chf total collection trade receivables december collateral held trade receivables none aaarange aarange since financial difficulties southern european countries notably spain italy greece portugal group arange leading supplier healthcare sectors countries trade receivables chf billion chf billion bbbrange public private customers countries group uses different measures improve collections countries bbbrange including intense communication customers factoring negotiations payments plans charging interest late payments unrated legal action total master netting agreements group enters derivative transactions collateral agreements international swaps derivatives association isda master netting agreements respective counterparties order mitigate counterparty risk agreements amounts owed counterparty single day respect transactions outstanding currency aggregated single net amount payable one party isda agreements meet criteria offsetting balance sheet group currently enforceable right offset recognised amounts right offset enforceable occurrence future events default credit events contract terms december significant financial assets whose terms renegotiated none impairment losses total impairment losses availableforsale financial assets amounted chf million chf million roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group liquidity risk market risk liquidity risk arises surplus financial obligations available financial assets due point time groups market risk arises changing market prices mainly foreign exchange rates interest rates groups financial assets approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time financial liabilities affect groups financial result equity roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements december group unused valueatrisk group uses valueatrisk var measure impact market risk financial instruments var indicates committed credit lines various financial institutions totalling chf billion chf billion chf billion serve value range within given financial instrument fluctuate preset probability result movements market backstop line commercial paper program prices var calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period remaining undiscounted cash flow contractual maturities financial liabilities including estimated interest payments shown trading days past ten years holding period reflects time required change corresponding risk exposure table deemed appropriate contractual maturities financial liabilities millions chf actual future gains losses associated treasury activities may differ materially var analyses due inherent limitations associated predicting timing amount changes interest rates foreign exchange rates equity investment carrying less value total year years years years prices particularly periods high market volatilities furthermore var include effect changes credit spreads year ended december debt market risk financial instruments millions chf bonds notes debt contingent consideration var interest rate component accounts payable var foreign exchange component derivative financial instruments var price component total financial liabilities diversification var total market risk year ended december debt interest rate component increased mainly due gradual increase longterm interest rates major economies foreign bonds notes exchange component remained largely stable price component arises mainly movements equity security prices debt remained largely stable contingent consideration accounts payable derivative financial instruments foreign exchange risk total financial liabilities group uses swiss franc reporting currency result exposed movements foreign currencies mainly us dollar japanese yen euro objective groups foreign exchange risk management activities preserve economic takeorpay commitments group entered contract manufacturing agreements various companies develop value current future assets minimise volatility groups financial result primary focus groups foreign manufacturing capacity flexibility future minimum takeorpay commitments within agreements total exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions potential commitment group chf billion december chf billion mainly related two contract held foreign currencies group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction manufacturing agreements pharmaceuticals division effect respectively exposures application instruments intends continuously lock favourable developments foreign exchange rates thereby reducing exposure potential future movements rates interest rate risk group mainly raises debt fixed rate basis bonds notes group exposed movements interest rates mainly us dollar swiss franc euro floating rate financial instruments primary objective groups interest rate management protect net interest result group may use forward contracts options swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group price risk financial instrument accounting classifications fair values price risk arises mainly movements prices equity securities group manages price risk placing limits fair values financial assets liabilities together carrying value shown consolidated balance sheet follows individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments carrying value fair value financial instruments millions chf fair value total available hedging fair value loans financial carrying capital management forsale instruments designated receivables liabilities value fair value year ended december group defines capital manages groups total capitalisation sum debt plus equity including non noncurrent assets controlling interests groups objectives managing capital availableforsale investments safeguard groups ability continue going concern continue provide benefits patients returns financial noncurrent assets investors accounts receivable provide adequate return investors based level risk undertaken marketable securities available necessary financial resources allow group invest areas may deliver future benefits patients cash cash equivalents returns investors current assets maintain sufficient financial resources mitigate risks unforeseen events derivative financial instruments financial current assets capitalisation reported senior management part groups regular internal management reporting shown total financial assets table debt capital millions chf bonds notes debt contingent consideration capital reserves attributable roche shareholders accounts payable equity attributable noncontrolling interests derivative financial instruments total equity total financial liabilities total debt year ended december noncurrent assets capitalisation availableforsale investments financial noncurrent assets groups net equity significantly impacted genentech transaction see note accounts receivable marketable securities group subject regulatory capital adequacy requirements known financial services industry group majority cash cash equivalents shareholdings chugai foundation medicine see note chugai foundation medicine public companies current assets objectives policies processes managing capital determined local management derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities fair value bonds notes level calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group fair value hierarchy level fair values table analyses financial instruments carried fair value valuation method different levels defined follows details determination level fair value measurements set level quoted prices unadjusted active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities contingent consideration arrangements millions chf level unobservable inputs fair value hierarchy financial instruments millions chf january arising business combinations level level level total utilised year ended december total unrealised gains losses included income statement marketable securities unused amounts reversed equity securities additional amount created debt securities discount unwind included financing costs money market instruments time accounts three months total gains losses included comprehensive income derivative financial instruments currency translation effects availableforsale investments held fair value december financial assets recognised fair value derivative financial instruments contingent consideration contingent consideration arrangements financial liabilities recognised fair value group party certain contingent consideration arrangements arising business combinations fair values determined year ended december considering expected payments discounted present value using riskadjusted average discount rate marketable securities expected payments determined considering possible scenarios forecast sales performance criteria amount equity securities paid scenario probability scenario significant unobservable inputs forecast sales debt securities performance criteria riskadjusted discount rate estimated fair value would increase forecast sales performance money market instruments time accounts three months criteria rates higher riskadjusted discount rate lower december total potential payments contingent derivative financial instruments consideration arrangements could chf billion chf billion follows availableforsale investments held fair value financial assets recognised fair value potential payments contingent consideration arrangements millions chf derivative financial instruments acquisition year acquired operating segment contingent consideration seragon roche pharmaceuticals financial liabilities recognised fair value trophos roche pharmaceuticals dutalys roche pharmaceuticals level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper santaris roche pharmaceuticals certificates deposit derivative financial instruments genia diagnostics geneweave diagnostics group determines level fair values using following valuation techniques cmi diagnostics marketable securities derivative financial instruments based valuation models use observable market data interest ariosa diagnostics rates yield curves foreign exchange rates implied volatilities similar instruments measurement date others diagnostics availableforsale investments based valuation model derived recently published observable financial prices december group recognises transfers levels fair value hierarchy end reporting period transfer occurred significant transfers level level vice versa year none derivative financial instruments group entered various currency swaps certain nonus dollar debt instruments cash collateral agreements entered counterparties currency swaps mitigate counterparty risk following table sets carrying value derivative financial instruments amounts subject master netting agreements roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group derivative financial instruments millions chf undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity assets liabilities foreign currency derivatives expected cash flows qualifying cash flow hedges impact profit loss millions chf forward exchange contracts crosscurrency swaps less less total year year total year year interest rate derivatives cash inflows swaps cash outflows total cash inflow outflow derivatives carrying value derivative financial instruments changes hedging reserve within equity shown note derivatives subject master netting agreements collateral arrangements fair value hedges group entered interest rate swaps hedge fixedterm debt instruments net amount december instruments recorded fair value liabilities chf million chf million fair value assets chf million chf million loss chf million recorded interest rate swaps gain chf million fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments collateral arrangements net investment hedges group net investment hedges due date march group redeemed fixed rate notes principal eur billion result hedges terminated cash received group counterparties movements cash collateral receivable accrued liability millions chf related parties january net cash delivered group controlling shareholders december share capital roche holding ltd groups parent company consists bearer shares december based information supplied group shareholder group pooled voting rights owned hedge accounting shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas december group following cash flow hedges fair value hedges designated qualifying hedge duschmal charitable foundation wolf shareholder pooling agreement existed since figures relationship include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool cash flow hedges group entered crosscurrency swaps hedge foreign exchange interest rate risk bonds notes issued group denominated euro pound sterling december instruments mr andr hoffmann dr andreas oeri members board directors roche holding ltd mr hoffmann received recorded net fair value liability chf million chf million ineffective portion remuneration totalling chf chf dr oeri received remuneration totalling chf chf chugai entered foreign exchange forward contracts hedge part foreign translation exposure swiss franc transactions group individual members shareholder group exception us dollar december instruments recorded fair value assets chf million fair value liabilities dr jrg duschmal works postdoc roche chf million ineffective portion expected undiscounted cash flows qualifying cash flow hedges including interest payments duration subsidiaries associates derivative contract final settlement maturity shown table listing major group subsidiaries associates included note transactions parent company expected cash flows qualifying cash flow hedges millions chf subsidiaries subsidiaries eliminated consolidation significant transactions group associates less less total year year total year year cash inflows cash outflows total cash inflow outflow roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group key management personnel equity compensation plans members corporate executive committee received equity compensation shown following tables total remuneration key management personnel chf million chf million number rights options awards granted members corporate executive committee members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees dr franz members corporate executive committee cec roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance roche stocksettled stock appreciation rights contributions respect remuneration pays contributions pension postemployment benefit plans roche restricted stock unit plan chairman board directors members cec members cec also participate certain equity compensation roche performance share plan plans described terms vesting conditions fair value awards disclosed note new members cec included table full calendar year joined cec similarly members cec retiring part way year included full calendar year left cec contributions paid members corporate executive committee millions chf remuneration members board directors corporate executive committee millions chf roche connect salaries including cashsettled bonus bonus stock awards social security costs transactions former members board directors corporate executive committee pensions totalling chf million pensions postemployment benefits paid group former corporate executive committee members chf million equity compensation plans board fees employee benefits defined benefit plans total transactions group various defined benefit plans employees group described note purposes remuneration disclosures values equity compensation plans including bonus stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions subsidiaries associates detailed disclosures regarding executive remuneration required swiss law included remuneration report included annual report pages disclosures values equity compensation plans including bonus stock awards represent fair value employee receives taking account preliminary assessment completed listed companies performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel share capital equity interest country company city millions switzerland roche holding ltd basel chf reconciliation executive remuneration disclosures required swiss law millions chf stock exchange six swiss exchange zurich valor share valor genussschein isin share ch total remuneration members board directors corporate executive committee isin genussschein ch ifrs basis see table market capitalisation chf japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo deduct isin jp bonus stock awards ifrs basis market capitalisation jpy equity compensation plans ifrs basis united states foundation medicine inc cambridge usd add back stock exchange nasdaq stock code fmi bonus stock awards swiss legal basis market capitalisation usd equity compensation plans swiss legal basis total remuneration members board directors corporate executive committee swiss legal basis including social security costs board directors annual report corporate executive committee annual report bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april number awards fair value per award calculated grant date roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group share capital equity interest nonlisted companies country company city millions france institut roche sas boulognebillancourt eur share capital equity interest roche diabetes care france sas meylan eur country company city millions roche diagnostics france sas meylan eur algeria roche algrie spa hydra dzd roche sas boulognebillancourt eur argentina productos roche sa qumica e industrial tigre ars trophos sa marseille eur roche diabetes care argentina sa tigre ars georgia roche georgia llc tbilisi gel vanguardia en productos farmacuticos vanprofarma sa buenos aires ars germany ascur versicherungsvermittlungs gmbh grenzachwyhlen eur australia roche diabetes care australia pty limited bella vista aud galenus mannheim pharma gmbh mannheim eur roche diagnostics australia pty limited castle hill aud roche beteiligungs gmbh grenzachwyhlen eur roche products pty limited dee aud roche deutschland holding gmbh grenzachwyhlen eur austria dutalys gmbh vienna eur roche diabetes care deutschland gmbh mannheim eur roche austria gmbh vienna eur roche diabetes care gmbh mannheim eur roche diagnostics gmbh vienna eur roche diagnostics deutschland gmbh mannheim eur azerbaijan roche azerbaijan llc baku azn roche diagnostics gmbh mannheim eur bangladesh roche bangladesh limited dhaka bdt roche diagnostics solutions gmbh berlin eur belarus fllc roche products limited minsk usd roche mtm laboratories ag mannheim eur belgium nv roche sa brussels eur roche pharma ag grenzachwyhlen eur roche diagnostics belgium nv brussels eur roche pvt gmbh waiblingen eur bermuda chemical manufacturing trading company limited hamilton usd roche real estate services mannheim gmbh mannheim eur hoffmannla roche products limited hamilton usd signature diagnostics gmbh potsdam eur roche capital services ltd hamilton rub ghana roche products ghana limited accra ghs roche catalyst investments ltd hamilton usd greece roche hellas sa athens eur roche financial investments ltd hamilton usd roche diagnostics hellas sa athens eur roche financial management ltd hamilton usd guatemala productos roche guatemala sa guatemala gtq roche financial services ltd hamilton usd honduras productos roche honduras sa tegucigalpa hnl roche international ltd hamilton usd hungary roche hungary ltd budapest huf roche intertrade limited hamilton usd roche services europe ltd budapest huf roche operations ltd hamilton usd india roche diabetes care india private limited mumbai inr roche services holdings ltd hamilton usd roche diagnostics india private limited mumbai inr syntex pharmaceuticals international ltd hamilton usd roche products india private limited mumbai inr bolivia roche bolivia srl santa cruz bob indonesia pt roche indonesia jakarta idr bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam iran roche pars co ltd tehran irr brazil produtos roche qumicos e farmacuticos sa paulo brl ireland roche ireland limited clarecastle eur roche diabetes care brasil ltda paulo brl roche products ireland limited dublin eur roche diagnostica brasil ltda paulo brl israel medingo ltd yoqneam illit ils bulgaria roche bulgaria eood sofia bgn roche pharmaceuticals israel ltd hod hasharon ils cameroon roche cameroun sarl douala xaf italy roche diabetes care italy spa monza eur canada chempharm limited mississauga cad roche diagnostics spa monza eur hoffmannla roche limited mississauga cad roche spa monza eur sapac corporation ltd hamilton cad japan roche dc japan k k tokyo jpy chile roche chile limitada santiago de chile clp roche diagnostics kk tokyo jpy china roche china holding ltd shanghai usd jordan f hoffmannla roche ltd jordan psc amman jod roche diagnostics hong kong limited hong kong hkd kazakhstan roche kazakhstan llp almaty kzt roche diagnostics shanghai limited shanghai usd kenya roche kenya limited nairobi kes roche diagnostics suzhou limited suzhou usd latvia roche latvija sia riga eur roche hong kong limited hong kong hkd lebanon roche lebanon sarl beirut lbp roche rd center china ltd shanghai usd lithuania uab roche lietuva vilnius eur shanghai ien pharma co ltd shanghai cny macedonia roche makedonija dooel skopje eur shanghai roche pharmaceuticals limited shanghai usd malaysia roche malaysia sdn bhd kuala lumpur myr colombia productos roche sa bogot cop roche diagnostics malaysia sdn bhd petaling jaya myr costa rica roche servicios sa heredia usd roche services asia pacific sdn bhd kuala lumpur myr cte divoire roche cte divoire sarl abidjan xof syntex pharmaceuticals sdn bhd kuala lumpur myr croatia roche doo zagreb hrk mauritius roche products mauritius ltd quatre bornes mur czech republic roche sro prague czk mexico productos roche sa de cv mexico city mxn denmark roche medicinalvarer og kemikalier hvidovre dkk roche servicios de mxico sa de cv mexico city mxn roche diagnostics hvidovre dkk moldova roche products limited srl chisinau mdl roche innovation center copenhagen hoersholm dkk morocco roche sa casablanca mad dominican republic productos roche dominicana srl santo domingo dop myanmar roche myanmar company limited yangon usd ecuador roche ecuador sa quito usd netherlands kapa biosystems bv amsterdam usd egypt roche egypt manufacturing trading sae cairo egp roche diabetes care nederland bv almere eur roche egypt llc cairo egp roche diagnostics nederland bv almere eur rodiagnostics egypt trading sae giza egp roche finance europe bv woerden eur el salvador productos roche el salvador sa de cv san salvador svc roche nederland bv woerden eur estonia roche eesti tallinn eur roche pharmholding bv woerden eur finland roche diagnostics oy espoo eur new zealand roche diagnostics nz limited auckland nzd roche oy espoo eur roche products new zealand limited auckland nzd roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group share capital equity interest share capital equity interest country company city millions country company city millions nicaragua productos roche nicaragua sa managua nio united arab emirates roche diabetes care middle east fzco dubai aed nigeria roche products limited lagos ngn roche diagnostics middle east fzco dubai aed norway roche diagnostics norge oslo nok roche middle east fzco dubai aed roche norge oslo nok roche pharmaceuticals middle east fzco dubai aed pakistan roche pakistan limited karachi pkr united kingdom intermune bristol limited welwyn garden city gbp palestine roche pharmaceuticals palestine ltd ramallah albireh usd intermune holdings limited welwyn garden city gbp panama productos roche panama sa panama city pab intermune uk limited welwyn garden city gbp productos roche interamericana sa prisa panama city usd intermune uk limited welwyn garden city gbp peru productos roche qumica farmacutica sa lima pen kapa biosystems ltd london gbp roche farma peru sa lima pen piramed limited welwyn garden city gbp philippines roche philippines inc taguig city php roche diabetes care limited burgess hill gbp poland roche diabetes care polska sp z oo warsaw pln roche diagnostics ltd burgess hill gbp roche diagnostics polska sp z oo warsaw pln roche holding uk limited welwyn garden city gbp roche polska sp z oo warsaw pln roche products limited welwyn garden city gbp portugal roche farmacutica qumica lda amadora eur roche registration limited welwyn garden city gbp roche sistemas de diagnsticos sociedade unipessoal lda amadora eur united states life sciences corporation little falls usd puerto rico roche products inc ponce usd adheron therapeutics inc wilmington usd syntex puerto rico inc ponce usd anadys pharmaceuticals inc south san francisco usd romania roche romania srl bucharest ron ariosa diagnostics inc san jose usd russian federation limited liability company roche diabetes care rus moscow rub bina technologies inc belmont usd limited liability company roche diagnostics rus moscow rub bioveris corporation indianapolis usd roche moscow ltd moscow rub forsight vision inc south san francisco usd serbia roche doo beograd belgrade eur genentech usa inc south san francisco usd singapore roche diabetes care asia pacific pte ltd singapore sgd genentech inc south san francisco usd roche diagnostics asia pacific pte ltd singapore sgd geneweave biosciences inc los gatos usd roche singapore pte ltd singapore sgd genia technologies inc santa clara usd roche singapore technical operations pte ltd singapore usd hlr consumer health inc little falls usd slovakia roche slovensko sro bratislava eur hoffmannla roche inc little falls usd slovenia roche farmacevtska druzba doo ljubljana eur igen international inc pleasanton usd south africa kapa biosystems pty ltd cape town zar intermune inc south san francisco usd roche diabetes care south africa pty ltd randburg zar iquum inc marlborough usd roche products proprietary limited illovo zar kapa biosystems inc wilmington usd south korea roche diagnostics korea co ltd seoul krw memory pharmaceuticals corp little falls usd roche korea company ltd seoul krw roche carolina inc florence usd spain emminens healthcare services sl madrid eur roche diabetes care inc indianapolis usd roche diabetes care spain sl barcelona eur roche diagnostics corporation indianapolis usd roche diagnostics sl barcelona eur roche diagnostics hematology inc westborough usd roche farma sa madrid eur roche diagnostics operations inc indianapolis usd sri lanka roche products colombo private limited colombo lkr roche health solutions inc indianapolis usd sweden roche ab stockholm sek roche holdings inc south san francisco usd roche diagnostics scandinavia ab bromma sek roche laboratories inc little falls usd switzerland biopharm ag basel chf roche molecular systems inc pleasanton usd f hoffmannla roche ltd basel chf roche palo alto llc south san francisco usd hoffmannla roche ltd basel chf roche sequencing solutions inc pleasanton usd intermune international ag basel chf roche tcrc inc new york usd museum tinguely ag basel chf seragon pharmaceuticals inc south san francisco usd phaor ag basel chf spring bioscience corp pleasanton usd rabbitair ltd bachenblach chf tensha therapeutics inc south san francisco usd roche capital market ltd basel chf ventana medical systems inc tucson usd roche chemische unternehmungen ag basel chf uruguay roche international ltd montevideo branch montevideo uyu roche diabetes care switzerland ltd rotkreuz chf venezuela productos roche sa caracas vef roche diabetes care ltd rotkreuz chf vietnam roche vietnam co ltd ho chi minh city usd roche diagnostics switzerland ltd rotkreuz chf share capital less local currency units roche diagnostics international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf syntex pharm ag rotkreuz chf tavero ag basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey roche diagnostics turkey anonim sirketi istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group significant accounting policies cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered consolidation policy royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred subsidiaries companies group control group controls entity group exposed rights variable returns involvement entity ability affect returns power entity companies acquired year consolidated date control transferred group subsidiaries research development divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions internal research development activities expensed incurred following occur control already obtained result loss control associates companies internal research costs incurred purpose gaining new scientific technical knowledge understanding group exercises power exercise significant influence control accounted using internal development costs incurred application research findings knowledge plan develop new products equity method commercial production development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation intangible assets met prior obtaining marketing approval regulatory authorities major markets segment reporting postmarketing studies regulatory approval phase iv costs pharmaceuticals business generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required purpose segment reporting groups corporate executive committee cec considered groups chief operating regulatory authorities may undertaken safety commercial reasons costs postmarketing studies decision maker determination groups operating segments based organisation units information reported capitalised intangible assets opinion management generate separately identifiable incremental future cec regular basis information provided used basis segment revenue profit disclosures reported economic benefits reliably measured note geographic analysis based location customers selected segment balance sheet information also routinely provided cec acquired inprocess research development resources obtained inlicensing arrangements business combinations separate asset purchases capitalised intangible assets acquired asset must controlled group separately transfer prices operating segments set arms length basis operating assets liabilities consist property plant identifiable expected generate future economic benefits even uncertainty exists whether research development equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products reasonably attributed reported operating segments nonoperating assets liabilities mainly include current compounds regulatory marketing approval recognised intangible assets assets acquired arrangements deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable measured basis set intangible assets policy subsequent internal research development costs incurred post securities investments debt acquisition treated way internal research development costs research development embedded contracts strategic alliances group carefully assesses whether upfront milestone payments constitute funding research development work acquisition asset foreign currency translation annual financial statements presented swiss francs group companies use local currency functional licensing milestone upfront receipts currency certain group companies use currencies us dollar swiss franc euro functional currency currency primary economic environment entity operates local transactions currencies initially royalty income recognised accrual basis accordance substance respective licensing agreements reported using exchange rate date transaction gains losses settlement transactions gains collectability royalty amount reasonably assured royalties recognised revenue cash received certain losses translation monetary assets liabilities denominated currencies included income except group companies receive upfront milestone similar payments third parties relating sale licensing products qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity technology revenue associated performance milestones recognised based achievement deliverables defined cases gains losses deferred comprehensive income respective agreements upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period development collaboration manufacturing upon consolidation assets liabilities group companies using functional currencies swiss francs translated swiss obligation francs using yearend rates exchange income statement statement cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly comprehensive income employee benefits shortterm employee benefits include wages salaries social security contributions paid annual leave sick leave profit sharing revenues bonuses nonmonetary benefits current employees costs recognised within operating results employee rendered associated service group recognises liability profit sharing bonuses contractually obliged sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts past practice created constructive obligation volume rebates exclude value added taxes taxes directly linked sales revenues sale products recognised upon transfer customer significant risks rewards trade discounts cash discounts volume rebates longterm employee benefits include longservice sabbatical leave longservice benefits longterm disability benefits recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks expected costs benefits accrued period employment changes carrying value longterm rebates including medicaid us similar rebates countries also deducted sales recorded employee benefit liabilities recognised within operating results accrued liabilities provisions deduction accounts receivable estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience circumstances level sales termination benefits payable employment terminated group normal retirement date whenever returns hence revenues reliably measured sales recognised right return expires employee accepts voluntary redundancy exchange benefits termination costs recognised earlier generally upon prescription products patients revenues recorded earned services performed single group longer withdraw offer benefits group recognises related restructuring costs transactions split separately identifiable components reflect substance transaction necessary conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group pensions postemployment benefits leases defined contribution plans group contributions recognised within operating results employee rendered group lessee finance leases exist substantially risks rewards ownership transferred associated service prepaid contributions recognised asset extent cash refund reduction future group finance leases capitalised start lease fair value present value minimum lease payments lower payments available rental obligation net finance charges reported within debt finance lease assets depreciated shorter lease term useful life interest element lease payment charged income lease term based effective defined benefit plans liability recognised balance sheet present value defined benefit obligation less fair interest rate method operating leases exist substantially risks rewards ownership transferred group value plan assets changes net defined benefit liability recognised occur follows payments made operating leases charged income straightline basis period lease recognised income statement group lessor certain assets mainly diagnostics instruments leased third parties finance current service costs charged appropriate income statement heading within operating results operating lease arrangements finance lease assets reported receivables amount equal net investment lease past service costs including curtailment gains losses recognised immediately general administration within operating lease income finance leases recognised term lease based effective interest rate method operating lease results assets reported within property plant equipment lease income operating leases recognised lease term settlement gains losses recognised general administration within operating results straightline basis net interest net defined benefit liability recognised financing costs recognised comprehensive income business combinations actuarial gains losses arising experience adjustments difference previous assumptions actually occurred changes actuarial assumptions business combinations accounted using acquisition method accounting date acquisition group initially return plan assets excluding amounts included net interest net defined benefit liability recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest acquired change limit recognition plan assets excluding amounts included net interest net defined benefit liability business consideration transferred measured fair value date acquisition group acquire ownership acquired business noncontrolling interests recorded either fair value proportion fair value net interest net defined benefit liability comprised interest income plan assets interest cost defined benefit acquired net assets attributable noncontrolling interest directly attributable acquisitionrelated costs expensed obligation interest effect limit recognition pension assets net interest calculated using incurred within general administration expenses discount rate used calculating defined benefit obligation applied net defined liability start period taking account changes contribution benefit payments goodwill pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan goodwill arises business combination excess consideration transferred acquire business underlying fair value net identified assets acquired goodwill amortised tested impairment least annually upon occurrence indication impairment equity compensation plans fair value equity compensation awards granted employees estimated grant date recorded expense intangible assets vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded purchased patents licences trademarks intangible assets initially recorded cost assets acquired changes equity business combination initially recorded fair value available use intangible assets amortised straight line basis useful lives intangible assets reviewed impairment reporting date estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated property plant equipment useful lives major classes amortisable intangible assets follows property plant equipment initially recorded cost purchase construction include costs directly attributable product intangibles use years bringing asset location condition necessary capable operating manner intended management marketing intangibles use years include items costs site preparation installation assembly costs professional fees net costs testing technology intangibles use years whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated impairment property plant equipment intangible assets useful lives major classes depreciable assets follows impairment assessment carried evidence asset may impaired addition intangible assets land improvements years yet available use tested impairment annually recoverable amount asset higher fair value buildings years less costs disposal value use less carrying value carrying value reduced recoverable amount machinery equipment years reduction reported income statement impairment loss value use calculated using estimated cash flows generally diagnostic instruments years fiveyear period extrapolating projections subsequent years discounted using appropriate longterm office equipment years interest rate impairment loss arises useful life asset reviewed necessary future depreciation motor vehicles years amortisation charge accelerated amount impairment loss subsequently decreases decrease related objectively event occurring impairment recognised previously recognised impairment loss reversed parts item property plant equipment different useful lives accounted separate components income statement impairment reversal estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group impairment goodwill financial instruments goodwill assessed impairment reporting date additionally tested annually impairment goodwill allocated financial instruments classified following categories disclosed note cashgenerating units recoverable amount cashgenerating unit higher fair value less costs disposal value use less carrying value carrying value goodwill reduced recoverable amount availableforsale nonderivative financial assets either designated classified reduction reported income statement impairment loss acquired business included within cash financial asset category availableforsale assets initially recorded subsequently carried fair value changes fair value generating unit permanently ceases operate treated disposal business separately identifiable goodwill recorded comprehensive income except impairments interest foreign exchange components investment generated initial acquisition business factors made goodwill entirely unrelated derecognised cumulative gains losses equity reclassified financial income expense availableforsale assets continuing operations cashgenerating unit goodwill deemed disposed fully impaired mainly comprised marketable securities impairment testing methodology described note fair value hedging instruments derivative financial instruments used manage exposures foreign currency interest rate equity market credit risks derivative financial instruments initially recorded subsequently carried fair value inventories apart derivatives designated qualifying cash flow hedging instruments changes fair value recorded financial income expense inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities fair value designated nonderivative financial instruments designated fair value profit loss initial cost determined using weighted average method net realisable value estimated selling price less cost completion recognition designated fair value instruments initially recorded subsequently carried fair value changes fair value selling expenses recorded income statement designated fair value instruments mainly comprised contingent consideration liabilities changes fair value recorded general administration within operating results accounts receivable loans receivables nonderivative financial assets fixed determinable payments quoted active market loans receivables initially recorded fair value subsequently carried amortised cost using effective interest accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash rate method less impairment losses loans receivables mainly comprised accounts receivable cash cash discounts volume rebates similar allowances allowance doubtful accounts recorded objective evidence equivalents group able collect amounts due estimates based specific indicators ageing customer balances specific credit circumstances groups historical experience taking also account economic conditions expenses financial liabilities nonderivative financial liabilities financial liabilities initially recorded fair value doubtful trade receivables recognised within marketing distribution expenses trade discounts cash discounts volume subsequently carried amortised cost using effective interest rate method financial liabilities mainly comprised debt rebates similar allowances recorded accrual basis consistent recognition related sales using estimates trade payables based existing contractual obligations historical trends groups experience financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership cash cash equivalents financial asset transferred financial liability derecognised contractual obligations discharged cancelled expire cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash equivalents readily convertible known amounts cash subject insignificant risk changes impairment financial assets fair value maturity three months less date acquisition financial assets individually assessed possible impairment reporting date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty available provisions contingencies forsale equity securities market value original cost market value original cost sustained sixmonth period considered impaired provisions recognised legal constructive obligation incurred probably lead outflow resources reliably estimated particular restructuring provisions recognised group detailed formal plan financial assets carried amortised cost impairment charge difference carrying value recoverable either commenced implementation announced provisions recorded estimated ultimate liability expected amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial arise discounted time value money material contingent liability disclosed existence obligation assets impairment charge amount currently carried comprehensive income difference original confirmed future events amount obligation measured reasonable reliability contingent cost fair value assets recognised disclosed inflow economic benefits probable impairment loss reversed reversal related objectively event occurring impairment loss recognised debt securities measured amortised cost availableforsale reversal recognised income equity securities held fair values availableforsale reversal recognised directly comprehensive income fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available roche finance report roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements roche group hedge accounting changes accounting policies group uses derivatives manage exposures foreign currency interest rate equity market credit risks instruments group implemented various minor amendments existing standards interpretations material impact used may include interest rate swaps crosscurrency swaps forwards contracts options group generally limits use groups overall results financial position hedge accounting certain significant transactions qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement many transactions considered hedges economic terms required conditions met relationship future new revised standards qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income group currently assessing potential impacts various new revised standards interpretations expense mandatory january group yet applied based analysis date group anticipate material impact groups overall results financial position cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecast transaction could affect profit loss hedging instrument recorded group also assessing new revised standards mandatory fair value effective portion hedge included comprehensive income ineffective portion reported financial income expense hedging relationship hedge foreign currency risk firm commitment highly probable ifrs financial instruments group plans implement new standard effective january apply exemption forecasted transaction results recognition nonfinancial item cumulative changes fair value hedging full retrospective application classification measurement requirements including impairment meaning instrument recorded comprehensive income included initial carrying value nonfinancial item comparative results restated new standard applied hedge accounting requirements applied date recognition cash flow hedges cumulative changes fair value hedging instrument prospectively new standard result increased volume disclosure information annual financial statements recorded comprehensive income included financial income expense forecasted transaction affects net income standard deals classification recognition measurement including impairment financial instruments gains fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm losses group currently recognises statement comprehensive income remeasuring assets classified commitment identified portion asset liability firm commitment attributable particular risk could affect availableforsale future recognised income statement assets classified fair value profit profit loss hedging instrument recorded fair value hedged item recorded previous carrying value adjusted loss equities fair value comprehensive income irrevocable option used impairment changes fair value attributable hedged risk changes fair values reported financial income expense financial assets including trade lease receivables assessed using expected loss model rather incurred loss model new standard also introduces new hedge accounting model requires hedge accounting relationships based upon groups risk management strategy objectives discontinued relationships longer qualify hedge debt accounting groups initial assessment existing hedge relationships continue designated new hedge accounting requirements debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised ifrs revenues contracts customers group plans implement new standard effective january duration debt instrument recognised part financing costs using effective interest rate method apply full retrospective method transition would normally mean comparative results would restated new standard applied however since group anticipate new standard actually change amounts revenue recognised restatement necessary group also plans use practical expedient taxation disclose amount transaction price allocated remaining performance obligations new standard result increased volume disclosure information annual financial statements income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general new standard contains new set principles recognise measure revenue well new requirements administration expenses related presentation core principle framework revenue recognised dependent transfer promised goods services customer amount reflects consideration received exchange goods liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating services objective standard provide fivestep approach revenue recognition includes identifying contracts subsidiaries recognised probable earnings remitted foreseeable future amount customers identifying performance obligations determining transaction prices allocating transaction prices performance obligations tax liabilities uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability recognising revenue performance obligations satisfied expected arise based specific circumstances groups historical experience ifrs leases group plans implement new standard effective january apply cumulative catchup deferred tax assets liabilities recognised temporary differences tax bases assets liabilities method transition meaning comparative results restated new standard applied new carrying values deferred tax assets recognised extent probable future taxable profit available standard result increased volume disclosure information annual financial statements unused tax losses utilised main impact new standard bring operating leases onbalance sheet group assessing potential impact current deferred tax assets liabilities offset income taxes levied taxation authority currently anticipates new standard result carrying value property plant equipment increased legally enforceable right offset deferred taxes determined based currently enacted tax rates applicable least chf billion debt increased similar amount application new standard result part currently tax jurisdiction group operates reported operating lease costs recorded interest expenses given leases involved current low interest rate environment group currently expect effect material equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments held groups potential conversion obligations may arise groups equity compensation plans roche finance report roche finance report roche group report roche management internal control financial reporting statutory auditors report roche group report roche management internal control financial reporting statutory auditors report general meeting roche holding ltd basel report roche management internal control financial reporting report audit consolidated financial statements board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting opinion standards audited consolidated financial statements roche holding ltd subsidiaries group comprise internal control systems matter well designed inherent limitations therefore even systems determined consolidated balance sheet december consolidated income statement consolidated statement effective may prevent detect misstatements provide reasonable assurance respect financial statement comprehensive income consolidated statement changes equity consolidated statement cash flows year preparation presentation also projections evaluation effectiveness future periods subject risk controls ended notes consolidated financial statements including summary significant accounting policies may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion consolidated financial statements pages give true fair view consolidated financial position group december consolidated financial performance consolidated cash flows year ended accordance international financial reporting standards ifrs comply swiss law management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework version issued committee sponsoring organizations treadway commission coso based assessment management basis opinion concluded system internal control financial reporting effective december conducted audit accordance swiss law international standards auditing isas swiss auditing statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended standards responsibilities provisions standards described auditors responsibilities december accordance swiss auditing standards international standards auditing isa audit consolidated financial statements section report independent group accordance also issued report effectiveness groups system internal control financial reporting report set provisions swiss law requirements swiss audit profession well iesba code ethics professional accountants fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion key audit matters christoph franz alan hippe chargebacks rebates sales returns us pharmaceuticals business chairman board directors chief financial officer basel january carrying value goodwill relating diagnostics division carrying value productrelated intangible assets provisions contingent liabilities respect litigations uncertain tax positions key audit matters matters professional judgement significance audit consolidated financial statements current period matters addressed context audit consolidated financial statements whole forming opinion thereon provide separate opinion matters roche finance report roche finance report roche group statutory auditors report statutory auditors report roche group chargebacks rebates sales returns us pharmaceuticals business carrying value goodwill relating diagnostics division key audit matter response key audit matter response groups pharmaceuticals business makes sales various audit procedures included amongst others testing group goodwill chf million arising audit procedures included amongst others testing customers us fall certain commercial groups key controls relating deductions made past acquisitions diagnostics division principally groups key controls surrounding carrying value governmentmandated contracts purchasing gross sales chargebacks rebates sales corangeboehringer mannheim ventana several goodwill relating diagnostics division reimbursement arrangements significant returns including controls accrual rates used businesses sequencing business area goodwill medicaid b drug discount program within managements calculations accrued liabilities assessed impairment reporting date audit goodwill included assessing groups group also provides right return us customers provisions deductions accounts receivable additionally tested annually impairment budgeting procedures upon forecasts based certain products return periods cases integrity discounted cash flow models extend several years future arrangements obtained managements calculations accrued impairment testing uses future cash flow projections based management used prepare valuations challenged result deductions gross amounts invoiced arriving liabilities provisions accounts receivable deductions recent business plans approved management robustness key assumptions used determine revenue create obligations group provide recalculated amounts validated assumptions including estimated sales volumes pricing business recoverable amounts including identification customers chargebacks rebates give used reference internal external sources including plans projected five years except sequencing allocation cgu forecast cash flows growth rates credit sales returns unsettled amounts estimated terms applicable contracts us government pricing business projected ten years reflecting long discount rates based understanding deducted gross sales recorded accrued liabilities information historical chargebacks rebates period required development technologies commercial prospects diagnostics businesses rebates provisions sales returns deduction historical sales returns levels current trends products necessary grow business markets operate accounts receivable chargebacks estimates based analyses existing contractual legislatively considered accuracy managements estimates management need apply considerable judgement using valuation specialists mandated obligations historical trends groups previous years comparing historical accrued liabilities allocating goodwill appropriate businesses well assist us evaluating assumptions methodologies experience provisions accounts receivable deductions recorded assessing future performance prospects used management particular relating actual amounts also assessed changes cashgenerating unit cgu discount rates discount rates comparing relevant assumptions management determined accrued liabilities accrual rates used within estimates including apply certain businesses face uncertainties technical industry economic forecasts addition identified deductions accounts receivable expected chargebacks responding increase utilisation b drug commercial viability leadingedge nextgeneration analysed changes assumptions prior periods rebates predominantly medicaid chf million discount program comparing accrual rates technologies products developed made assessment consistency assumptions necessary december additionally provisions current chargeback rebate payment sales performed comparison assumptions publicly sales returns mainly relating products near loss return trends focused area light amount judgement available data also performed retrospective exclusivity chf million recorded estimation required history impairments recorded assessment accuracy managements past december considered adequacy groups revenue previous years amounts headroom projections comparing historical forecasts actual recognition accounting policies including recognition cgus results focused area arrangements measurement deductions gross sales relating complex establishing appropriate year chargebacks rebates sales returns related forecasts supporting carrying value end position requires significant judgement estimation disclosures goodwill exceeded usual period five years management assumptions required estimating case goodwill relating sequencing provisions sales returns also made complicated business challenged management reasons given recent impending loss exclusivity us made assessment managements ability groups pharmaceutical products forecast cash flows longer periods reasonable accuracy information chargebacks rebates sales returns us pharmaceuticals business refer following also assessed whether groups disclosures sensitivity outcome impairment assessment significant accounting policies note general accounting principles key accounting judgements changes key assumptions reflect risks inherent estimates assumptions note pages financial disclosures note accounts receivable note valuation goodwill current liabilities note provisions contingent liabilities information carrying value goodwill relating diagnostics division refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note goodwill roche finance report roche finance report roche group statutory auditors report statutory auditors report roche group carrying value productrelated intangible assets provisions contingent liabilities respect litigations key audit matter response key audit matter response group significant productrelated intangible assets audit procedures included amongst others testing pharmaceuticals industry heavily regulated discussed status significant known actual december chf million acquired groups key controls surrounding carrying value increases inherent litigation risk normal course potential litigation inhouse legal counsel business combinations inlicensing arrangements productrelated intangible assets business provisions contingent liabilities may arise management directors knowledge comprise product intangibles use chf million productspecific general legal proceedings matters challenged decisions rationale amortised product intangibles available audit productrelated intangible assets use antitrust government investigations provisions held decisions record provisions use chf million amortised impairment included assessing groups process key controls december group held provisions chf make disclosures significant matters assessment carried productrelated intangibles identifying triggering events circumstances million respect legal actions given highly complex assessed relevant historical recent judgments evidence asset may impaired evidence asset may impaired nature regulatory legal cases management applies passed court authorities considered legal intangible assets yet available use also challenged robustness key assumptions used significant judgement considering whether opinion obtained management external lawyers tested impairment annually determine recoverable amounts including forecast much provide potential exposure matter challenge basis used provisions recorded revenues profit margins useful lives discount estimates could change substantially time disclosures made group product intangibles use chf million predominantly rates challenge based understanding new facts emerge legal case progresses relate acquired products launched commercial prospects individual products used forensic compliance specialists key risk ability successfully commercialise well relevant business areas markets focused area given number complexity assist assessment groups internal audit products concerned largest single intangible asset operate used valuation specialists assist magnitude potential exposures across group reports compliance logs reports prepared arose acquisition intermune relates us evaluating assumptions methodologies used judgement necessary determine whether management identify actual potential noncompliance esbriet chf million focused area given management particular relating discount amounts provide andor disclose laws regulations specific groups assessing recoverability product intangibles use rates made assessments relation key business relating conduct business based forecasting discounting future cash flows inputs projected pricing volumes products generally inherently highly judgemental key estimates projected share therapeutic area vitro diagnostic assumptions include revenue growth loss exclusivity market profit margin comparing relevant assumptions matters management concluded profit margins discount rates development industry forecasts reviewing analyst commentaries provisions recorded also considered commercialisation competing products retrospective assessment accuracy previous adequacy completeness groups disclosures projections considered higher risk made relation contingent liabilities product intangibles available use chf million impairment performed sensitivity analysis individual mostly represent inprocess research development intangible asset impairment models assess level information provisions contingent liabilities respect litigations refer following assets due inherent uncertainties research sensitivity key assumptions could focus work development processes intangible assets available areas significant accounting policies note general accounting principles key accounting judgements use particularly risk impairment impairment estimates assumptions note financial disclosures note provisions contingent liabilities assessment requires management make key assumptions regarding productrelated intangibles yet available judgements clinical technical commercial use audit addition procedures included viability new products accordingly also focused assessing reasonableness managements assumptions audit work areas risks include inability regarding probability obtaining regulatory approval achieve successful trial results obtain required clinical comparison industry practice past history regulatory approvals highly competitive business consideration groups internal governance environment therapeutic areas group approval processes also interviewed number senior significant assets research development research development commercial personnel order understand challenge assumptions information carrying value productrelated intangible assets refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note intangible assets roche finance report roche finance report roche group statutory auditors report statutory auditors report roche group information annual report uncertain tax positions board directors responsible information annual report information comprises information included annual report include consolidated financial statements standalone financial statements company remuneration report auditors reports thereon key audit matter response group operates across wide range different challenged managements judgement regarding opinion consolidated financial statements cover information annual report tax jurisdictions around world thus subject eventual resolution national tax authorities double express form assurance conclusion thereon occasional challenges local tax authorities including taxation conflicts pending tax audits estimates tax crossborder transfer pricing arrangements goods exposures assistance local country tax connection audit consolidated financial statements responsibility read information services financing transactionrelated tax matters specialists significant uncertain tax positions annual report consider whether information materially inconsistent consolidated financial connection integration investments divestments work included assessment thirdparty opinions statements knowledge obtained audit otherwise appears materially misstated based work licensing contracts areas particular focus include use available past experience performed conclude material misstatement information required report fact transfer pricing arrangements relating tax authorities respective jurisdiction additionally nothing report regard groups manufacturing supply chain used tax specialists expertise assess appropriateness key assumptions made amount tax liabilities uncertain group management conclude best estimate responsibility board directors consolidated financial statements recognises accruals reflect managements best estimate outcome outcome based facts known relevant board directors responsible preparation consolidated financial statements give true fair view jurisdiction group open tax transfer pricing audit approach included additional audit procedures accordance ifrs provisions swiss law internal control board directors determines matters various tax authorities range performed group level consider significant necessary enable preparation consolidated financial statements free material misstatement whether possible outcomes broad december uncertain tax positions particular transfer prices applied due fraud error group recognised current income tax liabilities goods services intellectual property rights chf million includes accruals uncertain preparing consolidated financial statements board directors responsible assessing groups ability tax positions continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate group cease operations realistic focused area estimates amounts alternative tax receivable payable require significant level expertise judgement auditors responsibilities audit consolidated financial statements information uncertain tax positions refer following objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion significant accounting policies note general accounting principles key accounting judgements reasonable assurance high level assurance guarantee audit conducted accordance swiss estimates assumptions note pages financial disclosures note income taxes law isas swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial statements part audit accordance swiss law isas swiss auditing standards exercise professional judgment maintain professional scepticism throughout audit also identify assess risks material misstatement consolidated financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made conclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease continue going concern roche finance report roche finance report roche group statutory auditors report report independent auditor internal control financial reporting roche group report independent auditor evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements represent underlying transactions events manner achieves fair presentation internal control financial reporting obtain sufficient appropriate audit evidence regarding financial information entities business activities within group express opinion consolidated financial statements responsible direction supervision performance group audit remain solely responsible audit opinion board directors roche holding ltd basel communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit examined roche groups system internal control financial reporting december based criteria established internal control integrated framework version issued committee sponsoring also provide board directors relevant committee statement complied relevant ethical organizations treadway commission coso requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable related safeguards board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included matters communicated board directors relevant committee determine matters accompanying report roche management internal control financial reporting responsibility express significance audit consolidated financial statements current period therefore key opinion groups internal control financial reporting based examination entitys internal control audit matters describe matters auditors report unless law regulation precludes public disclosure financial reporting process effected entitys board directors management personnel designed matter extremely rare circumstances determine matter communicated report provide reasonable assurance regarding reliability financial statements prepared accordance international adverse consequences would reasonably expected outweigh public interest benefits financial reporting standards ifrs includes policies procedures pertain maintenance communication records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention report legal regulatory requirements timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements accordance article para item co swiss auditing standard confirm internal control conducted examination accordance international standard assurance engagements isae system exists designed preparation consolidated financial statements according instructions standard requires plan perform examination obtain reasonable assurance whether effective board directors internal control financial reporting maintained material respects examination included obtaining understanding internal control financial reporting testing evaluating design operating effectiveness recommend consolidated financial statements submitted approved internal control performing procedures considered necessary circumstances believe evidence obtained examination provides reasonable basis opinion kpmg ag inherent limitations internal control financial reporting including possibility management override controls misstatements due error fraud may occur detected also projections evaluation internal control financial reporting future periods subject risk internal control may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework version issued ian starkey marc ziegler committee sponsoring organizations treadway commission coso licensed audit expert licensed audit expert auditor charge also audited accordance swiss auditing standards international standards auditing isa consolidated financial statements roche holding ltd year ended december report dated basel january january expressed unqualified opinion consolidated financial statements kpmg ag ian starkey marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved swiss legal entity rights reserved roche finance report roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information roche group alternative performance measures sales division millions chf pharmaceuticals diagnostics financial information included financial review includes certain alternative performance measures apms total accounting measures defined ifrs particular core results net working capital net operating assets free cash flow constant exchange rates apms used instead considered alternatives groups consolidated financial results based ifrs apms may comparable similarly titled measures disclosed companies apms sales geographical area millions chf presented financial review relate performance current year comparative periods switzerland core results germany rest europe core results allow assessment groups actual results defined ifrs underlying performance europe business core results concept used internal management business based ifrs results following adjustments united states global restructuring plans see note excluded rest north america amortisation impairment intangible assets see note impairment goodwill see note excluded north america acquisition accounting impacts accounting alliance arrangements business combinations see financial review excluded latin america discontinued operations currently none would excluded legal environmental cases see financial review excluded japan global issues outside healthcare sector beyond groups control currently none would excluded rest asia material treasury items major debt restructurings see note excluded asia pension plan settlements see note excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price africa australia oceania underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note total core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm additions property plant equipment division millions chf groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables additional commentary adjustment items given financial review pharmaceuticals diagnostics corporate total additions property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information roche group core results reconciliation millions chf divisional core results reconciliation millions chf alliances normali alliances global intangibles business legal major debt pension sation global intangibles business legal pension restruc amorti intangibles combi environ restruc plan ecp tax restruc amorti intangibles combi environ plan ifrs turing sation impairment nations mental turing settlements benefit core ifrs turing sation impairment nations mental settlements core sales pharmaceuticals royalties operating sales income royalties operating income cost sales cost sales marketing distribution marketing distribution research development research development general administration general administration operating profit operating profit financing costs diagnostics financial income sales expense royalties operating income profit taxes cost sales marketing distribution income taxes research development net income general administration operating profit attributable roche shareholders corporate noncontrolling interests general administration operating profit core results reconciliation millions chf divisional core results reconciliation millions chf alliances normali global intangibles business legal major debt pension sation alliances restruc amorti intangibles combi environ restruc plan ecp tax global intangibles business legal pension ifrs turing sation impairment nations mental turing settlements benefit core restruc amorti intangibles combi environ plan sales ifrs turing sation impairment nations mental settlements core royalties operating pharmaceuticals income sales cost sales royalties operating income marketing distribution cost sales research development marketing distribution general administration research development operating profit general administration operating profit financing costs financial income diagnostics expense sales profit taxes royalties operating income cost sales income taxes marketing distribution net income research development general administration attributable operating profit roche shareholders noncontrolling interests corporate general administration operating profit roche finance report roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information roche group core eps basic operating free cash flow free cash flow calculated shown tables additional commentary adjustment items given financial review core net income attributable roche shareholders chf millions operating free cash flow reconciliation millions chf weighted average number shares nonvoting equity securities issue millions core earnings per share basic chf cash flows operating activities ifrs basis accordance ias add back income taxes paid deduct core eps diluted investments property plant equipment investments intangible assets disposal property plant equipment core net income attributable roche shareholders chf millions disposal intangible assets increase noncontrolling interests share core net income assuming outstanding chugai stock pensions postemployment benefits options exercised chf millions add back total payments defined benefit plans net income used calculate diluted earnings per share chf millions deduct allocation payments operating free cash flow operating items weighted average number shares nonvoting equity securities issue used operating free cash flow calculate diluted earnings per share millions core earnings per share diluted chf free cash flow reconciliation millions chf free cash flow cash flows operating activities ifrs basis accordance ias deduct free cash flow used assess groups ability generate cash required conduct maintain operations also indicates investments property plant equipment groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities investments intangible assets free cash flow concept used internal management business disposal property plant equipment disposal intangible assets operating free cash flow calculated based ifrs operating profit adjusted certain cash items movements net working interest paid capital capital expenditures investments property plant equipment intangible assets operating free cash flow different operating items cash flows operating activities defined ias includes capital expenditures within responsibility treasury items divisional management excludes income taxes paid within responsibility divisional management cash outflows free cash flow defined benefit plans allocated operating free cash flow based current service cost residual allocated treasury activities free cash flow calculated operating free cash flow adjusted treasury activities taxes paid free cash flow different total cash flows defined ias excludes dividend payments cash inflowsoutflow financing activities issuancerepayment debt purchasesale marketable securities cash inflowsoutflows mergers acquisitions divestments group refined calculation free cash flow exclude dividends line peer group free cash flow restated accordingly resulting increase chf million free cash flow period impact operating free cash flow change roche finance report roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information roche group supplementary information used calculate divisional operating free cash flow shown table net operating assets divisional operating free cash flow information millions chf net operating assets allow assessment groups operating performance business independently financing tax activities net operating assets calculated property plant equipment goodwill intangible assets net working capital pharmaceuticals diagnostics corporate group longterm net operating assets minus provisions depreciation amortisation impairment depreciation property plant equipment calculation net operating assets disclosed note annual financial statements shown tables amortisation intangible assets impairment property plant equipment net operating assets reconciliation millions chf impairment goodwill taxation impairment intangible assets pharmaceuticals diagnostics corporate treasury roche group total property plant equipment goodwill adjustments intangible assets add back inventories expenses equitysettled equity compensation provisions plans current income tax net liabilities net income expense provisions deferred tax net assets net gain loss disposals defined benefit plan net liabilities noncash working capital items marketable securities deduct cash cash equivalents utilisation provisions debt proceeds disposals net assets liabilities total net working capital longterm net operating assets operating profit cash adjustments total net operating assets ebitda net operating assets reconciliation millions chf group use earnings interest tax depreciation amortisation ebitda either internal management taxation reporting external communications opinion groups management operating free cash flow gives useful pharmaceuticals diagnostics corporate treasury roche group consistent measurement cash earnings ebitda includes many noncash items provisions allowances trade property plant equipment receivables inventories certain noncash entries arising acquisition accounting pension accounting goodwill intangible assets convenience readers use ebitda provided table starting point uses core inventories results already exclude amortisation impairment goodwill intangible assets provisions current income tax net liabilities ebitda using core results millions chf deferred tax net assets defined benefit plan net liabilities pharmaceuticals diagnostics corporate group marketable securities ebitda cash cash equivalents core operating profit debt depreciation impairment property plant net assets liabilities equipment core basis net working capital ebitda longterm net operating assets margin sales total net operating assets roche finance report roche finance report roche group multiyear overview supplementary information roche securities roche group roche securities net debt net debt used monitor groups overall short longterm liquidity net debt calculated sum total debt longterm shortterm less marketable securities cash cash equivalents net debt calculations including details movements current year shown table financial review price development share chf net working capital net working capital used assess groups efficiency utilising assets shortterm liquidity net trade working capital iscalculated trade receivables inventories minus trade payables net working capital calculated net trade working capital adjusted receivables payables net working capital net trade working capital calculations shown tables pharmaceuticals division diagnostics division corporate financial review roche share swiss market index rebased constant exchange rates certain percentage changes financial review calculated using constant exchange rates cer allow assessment groups financial performance effects exchange rate fluctuations eliminated percentage changes price development nonvoting equity security genussschein chf constant exchange rates calculated using simulations reconsolidating current reported period prior period numbers constant currency exchange rates equalling average exchange rates prior year example cer change line item equivalent calculated using average exchange rate year ended december line item line item subsequently calculating change percent respect two recalculated numbers foreign exchange gains losses excluded calculation cer growth rates earning per share calculations countries significant devaluation local currency current year simulations use average exchange rate current year instead prior year avoid cer growth rates artificially inflated roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased eight roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july information tables restated change ratio adrs effective january change ratio adrs effective january change ratio adrs effective february roche finance report roche finance report roche group roche securities roche holding ltd basel number shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value financial statements total number shares nonvoting equity securities notes financial statements genussscheine held total issue summary significant accounting policies ignificant shareholders hareholders equity f ulltime equivalents contingent liabilities board executive shareholdings data per share nonvoting equity security chf appropriation available earnings earnings basic statutory auditors report general meeting roche holding ltd basel earnings diluted core earnings basic core earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypk roche finance report roche finance report roche holding ltd basel financial statements financial statements roche holding ltd basel financial statements income statement millions chf year ended december income income investments dividend income balance sheet millions chf financial income interest income loans group companies december december income marketable securities current assets guarantee fee income group companies cash cash equivalents income marketable securities total income accounts receivable group companies shortterm loans group companies expenses current receivables administration expenses total current assets expenses financial expenses noncurrent assets direct taxes longterm loans group companies total expenses investments total noncurrent assets net income total assets shortterm liabilities accounts payable group companies shortterm liabilities total shortterm liabilities longterm liabilities provisions total longterm liabilities total liabilities shareholders equity share capital nonvoting equity securities genussscheine pm pm legal retained earnings general legal retained earnings voluntary reserves retained earnings free reserve special reserve available earnings balance brought forward previous year net income year equity instruments total shareholders equity total shareholders equity liabilities pm pro memoria nonvoting equity securities nominal value roche finance report roche finance report roche holding ltd basel notes financial statements notes financial statements roche holding ltd basel notes financial statements equity instruments company purchase roche shares company sold roche shares roche shares average sales price chf per share chf per share net gain chf million net gain chf million dividend income amounted chf million chf million summary significant accounting policies december company hold roche shares december company held roche shares cost chf million deducted equity number equity instruments held company subsidiaries basis preparation excluding foundations meets definitions requirements article b co within roche group annual financial statements entities mainly foundations included consolidation qualify subsidiaries article b co financial statements roche holding ltd basel company prepared accordance provisions swiss law accounting financial reporting nd title swiss code obligations co prescribed law significant movement recognised amounts millions chf accounting principles applied described legal voluntary reserves retained earnings share retained free special available equity total company prepared consolidated financial statements accordance recognised accounting standard international capital earnings reserve reserve earnings instruments equity financial reporting standards accordance co company decided forgo presenting additional information audit fees january notes well cash flow statement net income dividends transactions equity instruments valuation methods translation foreign currencies december marketable securities reported lower cost market value financial assets including investments reported net income cost less appropriate writedowns equity instruments recognised cost deducted equity time purchase dividends equity instruments sold gain loss recognised income statement assets liabilities denominated transactions equity instruments foreign currencies translated swiss francs using yearend rates exchange except investments translated december historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception net income unrealised gains deferred dividends transactions equity instruments december investments major direct indirect investments company listed note roche group annual financial statements ownership interests equal voting rights contingent liabilities taxes guarantees direct taxes include corporate income capital taxes company issued guarantees certain bonds notes commercial paper credit facilities group companies nominal amount outstanding december chf billion chf billion described note roche group annual financial statements shareholders equity significant shareholders share capital previous year share capital amounts chf million share capital consists bearer shares nominal value chf included equity nonvoting equity securities genussscheine part share shares company bearer shares reason company keep register shareholders following capital confer voting rights however nonvoting equity security confers rights shares participate figures based information shareholders shareholder validation check annual general meeting march available earnings remaining proceeds liquidation following repayment nominal value share capital information available company participation certificates roche finance report roche finance report roche holding ltd basel notes financial statements notes financial statements roche holding ltd basel controlling shareholders corporate executive committee december based information supplied group shareholder group pooled voting rights owned members corporate executive committee persons closely associated held shares nonvoting equity securities shares represented issued shares group consisted ms vera michalskihoffmann ms maja shown table hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures shareholdings members corporate executive committee include shares without pooled voting rights held outside group individual members group ms maja oeri nonvoting equity securities formerly member pool holds shares representing voting rights independently pool shares genussscheine december based information supplied group shares shares owned novartis schwan holding ag basel participation ayyoubi na na r diggelmann hippe ga keller b oday fulltime equivalents ca wilbur na na total equity compensation awards ssars rsus roche performance share plan annual average number fulltime equivalents exceed ten people b close relatives dr keller held roche shares roche shares december members corporate executive committee held stocksettled stock appreciation rights ssars shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages board executive shareholdings ssars awards held december board directors year issue total schwan directors mr andr hoffmann dr andreas oeri certain members founders families closely associated r diggelmann belong shareholder group pooled voting rights end group held shares hippe issued shares detailed information group given note addition end year members board ga keller directors persons closely associated held shares nonvoting equity securities genussscheine shown oday table ca wilbur total cec annual general meeting march prof pius baschera stand reelection mrs anita hauser nominated election new member board directors strike price chf expiry date mar mar mar mar mar feb feb shareholdings members board directors december members corporate executive committee held restricted stock units rsus shown table nonvoting equity securities terms vesting conditions awards disclosed note roche group annual financial statements shares genussscheine additional supplementary information remuneration report included annual report pages rsus ch franz remuneration component corporate executive committee replaced awarding corresponding performance share plan hoffmann psp awards rsu awards vested recipient three years thereafter nonvoting equity securities may remain p baschera blocked ten years j bell j brown na na rsu awards held december p bulcke julius na na year issue total rp lifton schwan na oeri r diggelmann na b poussot hippe na schwan b ga keller na c sssmuth dyckerhoff na c na c oday na pr voser ca wilbur na b weder di mauro na na total cec na total include shares held shareholder group pooled voting rights b member corporate executive committee dr schwans shareholdings disclosed tables c jointly held close relative roche finance report roche finance report roche holding ltd basel notes financial statements appropriation available earnings roche holding ltd basel appropriation available earnings december members corporate executive committee shown table held psp awards psp performance cycles terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages award result zero two nonvoting equity securities shares value adjustment depending upon achievement performance targets discretion board directors vesting nonvoting equity securities shares may remain blocked ten years end cycle performance targets achieved accordingly participants received none originally targeted nonvoting equity securities total target number awards outstanding performance cycles december shown table roche performance share plan awards held december proposals annual general meeting chf psp psp schwan available earnings r diggelmann balance brought forward previous year hippe net profit year ga keller total available earnings oday ca wilbur appropriation available earnings total cec distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year allocation date feb feb total appropriation available earnings information relating number value rights options awards granted employees roche group members carried forward account board directors corporate executive committee company disclosed note note roche group annual financial statements roche finance report roche finance report roche holding ltd basel statutory auditors report statutory auditors report roche holding ltd basel statutory auditors report part audit accordance swiss law swiss auditing standards exercise professional judgment maintain professional scepticism throughout audit also identify assess risks material misstatement financial statements whether due fraud error design general meeting roche holding ltd basel perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override report audit financial statements internal control obtain understanding internal control relevant audit order design audit procedures appropriate opinion circumstances purpose expressing opinion effectiveness internal control audited financial statements roche holding ltd comprise balance sheet december evaluate appropriateness accounting policies used reasonableness accounting estimates related income statement year ended notes financial statements including summary significant disclosures made accounting policies conclude appropriateness board directors use going concern basis accounting based opinion financial statements pages year ended december comply swiss law audit evidence obtained whether material uncertainty exists related events conditions may cast significant companys articles incorporation doubt entitys ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date basis opinion auditors report however future events conditions may cause entity cease continue going concern conducted audit accordance swiss law swiss auditing standards responsibilities communicate board directors relevant committee regarding among matters planned scope provisions standards described auditors responsibilities audit financial statements timing audit significant audit findings including significant deficiencies internal control identify section report independent entity accordance provisions swiss law requirements audit swiss audit profession fulfilled ethical responsibilities accordance requirements also provide board directors relevant committee statement complied relevant ethical believe audit evidence obtained sufficient appropriate provide basis opinion requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable related safeguards report key audit matters based circular federal audit oversight authority matters communicated board directors relevant committee determine matters significance audit financial statements current period therefore key audit matters determined key audit matters communicate report describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication responsibility board directors financial statements board directors responsible preparation financial statements accordance provisions report legal regulatory requirements swiss law companys articles incorporation internal control board directors determines necessary enable preparation financial statements free material misstatement whether due fraud accordance article para item co swiss auditing standard confirm internal control error system exists designed preparation financial statements according instructions board directors preparing financial statements board directors responsible assessing entitys ability continue going concern disclosing applicable matters related going concern using going concern basis accounting confirm proposed appropriation available earnings complies swiss law companys articles unless board directors either intends liquidate entity cease operations realistic alternative incorporation recommend financial statements submitted approved kpmg ag auditors responsibilities audit financial statements objectives obtain reasonable assurance whether financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions ian starkey marc ziegler users taken basis financial statements licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche finance report roche finance report published cautionary statement regarding forwardlooking statements f hoffmannla roche ltd annual report contains certain forwardlooking statements group communications forwardlooking statements may identified words basel switzerland believes expects anticipates projects intends tel seeks estimates future similar expressions wwwrochecom discussion among things strategy goals plans intentions various factors may cause actual results differ orderdownload publications materially future reflected forwardlooking internet rochecompublications statements contained annual report among others email baselwarehouseservicesrochecom pricing product initiatives competitors legislative fax regulatory developments economic conditions delay inability obtaining regulatory approvals bringing products media relations market fluctuations currency exchange rates general tel financial market conditions uncertainties discovery email rochemediarelationsrochecom development marketing new products new uses existing products including without limitation negative results clinical investor relations trials research projects unexpected side effects pipeline tel marketed products increased government pricing pressures email investorrelationsrochecom interruptions production loss inability obtain adequate protection intellectual property rights litigation corporate sustainability committee loss key executives employees adverse tel publicity news coverage email corporatesustainabilityrochecom statement regarding earnings per share growth profit next annual general meeting forecast interpreted mean roches march earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share roche trademarks legally protected links thirdparty pages provided convenience express opinion content thirdparty pages expressly disclaim liability thirdparty information use roche finance report published german english case doubt differences interpretation english version shall prevail german text reporting consists actual annual report finance report contains annual financial statements consolidated financial statements regards content management report per articles incorporation consists aforementioned reports exception remuneration report printed nonchlorine bleached fsccertified paperf hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche finance report finance report